<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/76CD45AC-378E-4073-94E5-C7DFBA3B4719"><gtr:id>76CD45AC-378E-4073-94E5-C7DFBA3B4719</gtr:id><gtr:name>University of Turku</gtr:name><gtr:address><gtr:line1>Turun yliopisto</gtr:line1><gtr:postCode>FI-20014</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Finland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B61BFC8B-0441-4826-89CE-D97251FA9FCB"><gtr:id>B61BFC8B-0441-4826-89CE-D97251FA9FCB</gtr:id><gtr:name>Brain &amp; Behaviour Research Foundation</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9218106A-E8CE-46A5-AABC-B4C8ED148690"><gtr:id>9218106A-E8CE-46A5-AABC-B4C8ED148690</gtr:id><gtr:name>University of Amsterdam</gtr:name><gtr:address><gtr:line1>Liaison Office</gtr:line1><gtr:line2>PO Box 19268</gtr:line2><gtr:line4>Amsterdam</gtr:line4><gtr:line5>Amsterdam</gtr:line5><gtr:postCode>1000 GG</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/99A20F70-F6B7-43DE-94E4-7004FAE6291E"><gtr:id>99A20F70-F6B7-43DE-94E4-7004FAE6291E</gtr:id><gtr:name>Ludwig Maximilians University Munich</gtr:name><gtr:address><gtr:line1>Geschwister-Scholl-Platz 1</gtr:line1><gtr:postCode>D-80539</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B92C1E49-4D20-4A69-BDBE-BDEC1AE2A476"><gtr:id>B92C1E49-4D20-4A69-BDBE-BDEC1AE2A476</gtr:id><gtr:name>University Medical Centre Utrecht</gtr:name><gtr:address><gtr:line1>Unversity Medical Centre Utrecht</gtr:line1><gtr:line2>Rudolf Magnus Institute for Neuroscience</gtr:line2><gtr:line3>PO Box 85060</gtr:line3><gtr:postCode>NL-3508 AB</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0B92D4B2-4955-4E0E-A0B8-2511FE3C2422"><gtr:id>0B92D4B2-4955-4E0E-A0B8-2511FE3C2422</gtr:id><gtr:name>Koninklijke Philips Electronics N.V.</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/872D8701-44D2-4D3C-B113-A795FA40D61F"><gtr:id>872D8701-44D2-4D3C-B113-A795FA40D61F</gtr:id><gtr:name>University of Helsinki</gtr:name><gtr:address><gtr:line1>Siltavuorenpenger 20 C</gtr:line1><gtr:line4>Helsinki</gtr:line4><gtr:line5>FI-00170</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Finland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B80FA015-FF48-471E-839C-CB0CD2B7E9AD"><gtr:id>B80FA015-FF48-471E-839C-CB0CD2B7E9AD</gtr:id><gtr:name>Imanova</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1CC23DC2-3991-4123-B5F2-83C1F5793403"><gtr:id>1CC23DC2-3991-4123-B5F2-83C1F5793403</gtr:id><gtr:name>F. Hoffmann-La Roche AG</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/16FF2A20-AB90-4926-953D-029E14E82758"><gtr:id>16FF2A20-AB90-4926-953D-029E14E82758</gtr:id><gtr:name>Sylics</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/99E936B6-D5CB-477B-8E15-F6F0465C8967"><gtr:id>99E936B6-D5CB-477B-8E15-F6F0465C8967</gtr:id><gtr:name>Autonomous University of Madrid (UAM)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CE713D42-FE8A-4117-AB3C-224D5A93265A"><gtr:id>CE713D42-FE8A-4117-AB3C-224D5A93265A</gtr:id><gtr:name>Heinrich Heine University D?sseldorf</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/64BC5E73-972F-41E1-A12C-D97DC9BDFB93"><gtr:id>64BC5E73-972F-41E1-A12C-D97DC9BDFB93</gtr:id><gtr:name>MRC Clinical Sciences Centre</gtr:name><gtr:address><gtr:line1>Faculty of Medicine Imperial College</gtr:line1><gtr:line2>London Hammersmith Campus</gtr:line2><gtr:line3>Du Cane Road</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>W12 0NN</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/64BC5E73-972F-41E1-A12C-D97DC9BDFB93"><gtr:id>64BC5E73-972F-41E1-A12C-D97DC9BDFB93</gtr:id><gtr:name>MRC Clinical Sciences Centre</gtr:name><gtr:address><gtr:line1>Faculty of Medicine Imperial College</gtr:line1><gtr:line2>London Hammersmith Campus</gtr:line2><gtr:line3>Du Cane Road</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>W12 0NN</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/76CD45AC-378E-4073-94E5-C7DFBA3B4719"><gtr:id>76CD45AC-378E-4073-94E5-C7DFBA3B4719</gtr:id><gtr:name>University of Turku</gtr:name><gtr:address><gtr:line1>Turun yliopisto</gtr:line1><gtr:postCode>FI-20014</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Finland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B61BFC8B-0441-4826-89CE-D97251FA9FCB"><gtr:id>B61BFC8B-0441-4826-89CE-D97251FA9FCB</gtr:id><gtr:name>Brain &amp; Behaviour Research Foundation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9218106A-E8CE-46A5-AABC-B4C8ED148690"><gtr:id>9218106A-E8CE-46A5-AABC-B4C8ED148690</gtr:id><gtr:name>University of Amsterdam</gtr:name><gtr:address><gtr:line1>Liaison Office</gtr:line1><gtr:line2>PO Box 19268</gtr:line2><gtr:line4>Amsterdam</gtr:line4><gtr:line5>Amsterdam</gtr:line5><gtr:postCode>1000 GG</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/99A20F70-F6B7-43DE-94E4-7004FAE6291E"><gtr:id>99A20F70-F6B7-43DE-94E4-7004FAE6291E</gtr:id><gtr:name>Ludwig Maximilians University Munich</gtr:name><gtr:address><gtr:line1>Geschwister-Scholl-Platz 1</gtr:line1><gtr:postCode>D-80539</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B92C1E49-4D20-4A69-BDBE-BDEC1AE2A476"><gtr:id>B92C1E49-4D20-4A69-BDBE-BDEC1AE2A476</gtr:id><gtr:name>University Medical Centre Utrecht</gtr:name><gtr:address><gtr:line1>Unversity Medical Centre Utrecht</gtr:line1><gtr:line2>Rudolf Magnus Institute for Neuroscience</gtr:line2><gtr:line3>PO Box 85060</gtr:line3><gtr:postCode>NL-3508 AB</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0B92D4B2-4955-4E0E-A0B8-2511FE3C2422"><gtr:id>0B92D4B2-4955-4E0E-A0B8-2511FE3C2422</gtr:id><gtr:name>Koninklijke Philips Electronics N.V.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/872D8701-44D2-4D3C-B113-A795FA40D61F"><gtr:id>872D8701-44D2-4D3C-B113-A795FA40D61F</gtr:id><gtr:name>University of Helsinki</gtr:name><gtr:address><gtr:line1>Siltavuorenpenger 20 C</gtr:line1><gtr:line4>Helsinki</gtr:line4><gtr:line5>FI-00170</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Finland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B80FA015-FF48-471E-839C-CB0CD2B7E9AD"><gtr:id>B80FA015-FF48-471E-839C-CB0CD2B7E9AD</gtr:id><gtr:name>Imanova</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1CC23DC2-3991-4123-B5F2-83C1F5793403"><gtr:id>1CC23DC2-3991-4123-B5F2-83C1F5793403</gtr:id><gtr:name>F. Hoffmann-La Roche AG</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/16FF2A20-AB90-4926-953D-029E14E82758"><gtr:id>16FF2A20-AB90-4926-953D-029E14E82758</gtr:id><gtr:name>Sylics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/99E936B6-D5CB-477B-8E15-F6F0465C8967"><gtr:id>99E936B6-D5CB-477B-8E15-F6F0465C8967</gtr:id><gtr:name>Autonomous University of Madrid (UAM)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CE713D42-FE8A-4117-AB3C-224D5A93265A"><gtr:id>CE713D42-FE8A-4117-AB3C-224D5A93265A</gtr:id><gtr:name>Heinrich Heine University D?sseldorf</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/93DFBBCC-4BFF-4D72-A55A-C63D84DD645B"><gtr:id>93DFBBCC-4BFF-4D72-A55A-C63D84DD645B</gtr:id><gtr:firstName>Oliver</gtr:firstName><gtr:surname>Howes</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U120097115"><gtr:id>465E7A25-043D-4AE2-AE76-FB79F49F011B</gtr:id><gtr:title>Psychiatric Imaging</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U120097115</gtr:grantReference><gtr:abstractText>Psychotic illnesses such as schizophrenia are common and amongst the top ten greatest causes of adult disability in the world. We urgently need new and better treatments. However, a major limit on developing better treatments is that we dont understand what leads to psychosis. The brain chemical messenger, dopamine, is known to be abnormal in the condition. It is also known that cannabis use, and some forms of social stress, increase the risk of psychosis. We aim to study how these risk factors affect the dopamine system, and see if differences in dopamine function explain why some vulnerable people develop psychosis and others do not. We also know that current treatments act down-stream of the dopamine abnormality, but it is not clear whether they make this abnormality better or worse. We will test whether the dopamine system is different in patients who do not respond to treatment, and if treatment increases the dopamine abnormality. Finally we will also test whether we can counter the dopamine abnormality by targeting its control mechanisms. These studies will help predict and prevent psychosis, and develop better treatments.</gtr:abstractText><gtr:technicalSummary>Psychotic disorders such as schizophrenia are amongst the top ten causes of disability in adults- accounting for one in every ten hospital beds used in the UK. The main treatments, the antipsychotic drugs, were discovered over fifty years ago. Since then there has been limited progress as: i) the medications are still based on the same old principle (dopamine (DA) receptor blockade), ii) there are no good predictors of response so treatment proceeds by trial-and-error, and iii) current treatments are ineffective for one in three patients. A major limit for the development of new, rational treatments has been the lack of a defined etiology and limited knowledge of the pathophysiology of schizophrenia. As a result most drug development in the last fifty years has simply sought to emulate aspects of existing antipsychotics and/or has used empirical animal models (e.g.: conditioned avoidance response or PCP-induced locomotion) that were developed prior to clear knowledge of the pathophysiology.|However, there is now evidence of a defined neurochemical pathophysiology in psychosis. Over fifteen in vivo studies in the last decade point to one central fact: presynaptic DA dysfunction is the final common pathway leading to psychosis (data reviewed and synthesized in: Howes et al, B J Psuch, 2007 &amp;amp; Lyon et al. Schiz. Bull. doi:10.1093, 2009). For this reason understanding the causes and implications of presynaptic DA dysfunction is critical to the pathophysiology of psychosis and provides a framework for understanding risk factors, predicting onset and delivering new treatments as set out in a recent review of the area (Howes and Kapur, Schiz Bulletin, 2009). The programme is divided into four sections: (a) Risk factors to pathophysiology; (b) Predicting illness onset; (c) Pathophysiology to therapeutics; (d) Targets beyond dopamine.|The first section will investigate the effects of the two major environmental risk factors for psychosis - cannabis use and social stress/defeat - on DA function using F-DOPA and raclopride positron emission tomography (PET) in individuals exposed to these risk factors. Section 2 addresses the ultimate aim in therapeutics of psychosis - predicting and preventing its onset using PET and magnetic resonance imaging (MRI) to identify biomarkers and pathoetiological changes underlying the development of psychosis. One third of patients with established psychosis fail to respond to treatment. Section 3 will investigate the determinants and predictors of treatment response using PET and MR spectroscopy of dopamine and glutamate markers respectively. Section 4 investigates upstream modulators of DA to identify novel non-D2 targets for drug discovery using agents that act at DA autoreceptors and glutamatergic and other regulatory mechanisms.|These studies have the potential to identify prognostic markers for psychosis and new therapeutic avenues to treat established illness.|</gtr:technicalSummary><gtr:fund><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-06-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>7210748</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imanova</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Imanova PDE</gtr:description><gtr:id>D9763B28-6FC7-45FA-885B-8592164D2A7B</gtr:id><gtr:impact>Work in progress</gtr:impact><gtr:outcomeId>rW4C5UyKaQX-1</gtr:outcomeId><gtr:partnerContribution>Development and provision of PET tracer</gtr:partnerContribution><gtr:piContribution>Undertaking recruitment and measures in clinical population</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Brain &amp; Behaviour Research Foundation</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>In-SENS</gtr:description><gtr:id>906BC38F-828B-45DF-821C-A069DEBFE282</gtr:id><gtr:impact>Increased cadre of researchers with clinical translation skills</gtr:impact><gtr:outcomeId>ZW2TLo4aGdX-5</gtr:outcomeId><gtr:partnerContribution>Teaching and training and sharing data</gtr:partnerContribution><gtr:piContribution>Teaching and training and sharing data</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Helsinki</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>METSY</gtr:description><gtr:id>CD25E6DC-B5F5-44C4-9C88-9DF86156A423</gtr:id><gtr:impact>Harmonisation of data collection</gtr:impact><gtr:outcomeId>WhmvjVB8Nd2-1</gtr:outcomeId><gtr:partnerContribution>Sharing data and expertise on analysis</gtr:partnerContribution><gtr:piContribution>Sharing data and collaborating on developing a new diagnostic and predictive biomarker platform for psychosis and metabolic dysfunction</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Medical Center Utrecht (UMC)</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:department>Department of Psychiatry</gtr:department><gtr:description>Hallucinators study</gtr:description><gtr:id>ADDD342D-64EE-4F8C-A6A3-C87C2634B59D</gtr:id><gtr:impact>Publications in preparation</gtr:impact><gtr:outcomeId>eL11aLe1JxF-1</gtr:outcomeId><gtr:partnerContribution>Provision of a unique cohort of subjects, contributing towards the costs of the study and funding research workers to conduct the study</gtr:partnerContribution><gtr:piContribution>Acquiring and analysing data</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>In-SENS</gtr:description><gtr:id>CDD0BB83-5549-4C70-8749-2B6F0183C62C</gtr:id><gtr:impact>Increased cadre of researchers with clinical translation skills</gtr:impact><gtr:outcomeId>ZW2TLo4aGdX-9</gtr:outcomeId><gtr:partnerContribution>Teaching and training and sharing data</gtr:partnerContribution><gtr:piContribution>Teaching and training and sharing data</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Division of Psychology &amp; Language Sciences</gtr:department><gtr:description>Cannabis, ketamine and psychosis (UCL)</gtr:description><gtr:id>F9028263-0CF9-4524-BDFD-13357697096D</gtr:id><gtr:impact>Publications-
Freeman et al 2012 and others
 in submission</gtr:impact><gtr:outcomeId>YDQTMt9B3Pq-1</gtr:outcomeId><gtr:partnerContribution>Our partners recruited subjects</gtr:partnerContribution><gtr:piContribution>We conducted imaging</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Heinrich Heine University D?sseldorf</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>In-SENS</gtr:description><gtr:id>E829E164-D947-46F3-BEC5-7F7F506CB7A8</gtr:id><gtr:impact>Increased cadre of researchers with clinical translation skills</gtr:impact><gtr:outcomeId>ZW2TLo4aGdX-1</gtr:outcomeId><gtr:partnerContribution>Teaching and training and sharing data</gtr:partnerContribution><gtr:piContribution>Teaching and training and sharing data</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Helsinki</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>In-SENS</gtr:description><gtr:id>B8BB4C0A-8054-47E1-9F86-14E56F77AE05</gtr:id><gtr:impact>Increased cadre of researchers with clinical translation skills</gtr:impact><gtr:outcomeId>ZW2TLo4aGdX-8</gtr:outcomeId><gtr:partnerContribution>Teaching and training and sharing data</gtr:partnerContribution><gtr:piContribution>Teaching and training and sharing data</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Cognitive Neuroscience</gtr:department><gtr:description>Mood and cognition</gtr:description><gtr:id>4B9BF91C-178D-42FE-838B-3C790A4D42CB</gtr:id><gtr:impact>Publications-
Selvaraj et al Mol Psych 2012 and others in submission</gtr:impact><gtr:outcomeId>ogwi45e3wXw-1</gtr:outcomeId><gtr:partnerContribution>Our partners have undertaken the behavioural testing</gtr:partnerContribution><gtr:piContribution>We have undertaken the imaging side of the study</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>In-SENS</gtr:description><gtr:id>62FBDA77-E534-45BB-863E-7F7B3BDAF2E7</gtr:id><gtr:impact>Increased cadre of researchers with clinical translation skills</gtr:impact><gtr:outcomeId>ZW2TLo4aGdX-3</gtr:outcomeId><gtr:partnerContribution>Teaching and training and sharing data</gtr:partnerContribution><gtr:piContribution>Teaching and training and sharing data</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Psychiatry, Psychology &amp; Neuroscience</gtr:department><gtr:description>Psychosis CAG</gtr:description><gtr:id>E8CA56ED-4A65-40EE-B8BC-78B4E2EF76EF</gtr:id><gtr:impact>Publications:

Delusional ideation, manic symptomatology and working memory in a cohort at clinical high-risk for psychosis: A longitudinal study.
Broome MR, Day F, Valli I, Valmaggia L, Johns LC, Howes O, Garety P, McGuire PK.
Eur Psychiatry. 2010 Oct 8. [Epub ahead of print]
PMID: 20934858 [PubMed - as supplied by publisher]
Related citations
3.
A comprehensive review and model of putative prodromal features of bipolar affective disorder.
Howes OD, Lim S, Theologos G, Yung AR, Goodwin GM, McGuire P.
Psychol Med. 2010 Sep 14:1-11.

Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis.
Stone JM, Howes OD, Egerton A, Kambeitz J, Allen P, Lythgoe DJ, O'Gorman RL, McLean MA, Barker GJ, McGuire P.
Biol Psychiatry. 2010 Oct 1;68(7):599-602. Epub 2010 Jul 17.
PMID: 20638047 [PubMed - in process]
Related citations
6.
Abnormal frontostriatal interactions in people with prodromal signs of psychosis: a multimodal imaging study.
Fusar-Poli P, Howes OD, Allen P, Broome M, Valli I, Asselin MC, Grasby PM, McGuire PK.
Arch Gen Psychiatry. 2010 Jul;67(7):683-91.
PMID: 20603449

The dopamine hypothesis of schizophrenia: version III--the final common pathway.
Howes OD, Kapur S.
Schizophr Bull. 2009 May;35(3):549-62. Epub 2009 Mar 26. Review.
PMID: 19325164 [PubMed - indexed for MEDLINE]Free PMC ArticleFree text
Related citations
22.
Functionally defined regions may aid interpretation of striatal dopamine elevation in schizophrenia.
Egerton A, McGuire PK, Howes OD.
Schizophr Res. 2009 Apr;109(1-3):200. Epub 2009 Feb 27. No abstract available.
PMID: 19250801 [PubMed - indexed for MEDLINE]
Related citations
23.
Elevated striatal dopamine function linked to prodromal signs of schizophrenia.
Howes OD, Montgomery AJ, Asselin MC, Murray RM, Valli I, Tabraham P, Bramon-Bosch E, Valmaggia L, Johns L, Broome M, McGuire PK, Grasby PM.
Arch Gen Psychiatry. 2009 Jan;66(1):13-20.PMID: 1912468

Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis.
Fusar-Poli P, Howes OD, Allen P, Broome M, Valli I, Asselin MC, Montgomery AJ, Grasby PM, McGuire P.
Mol Psychiatry. 2009 Dec 1 PMID: 19949389</gtr:impact><gtr:outcomeId>WmE16jCBpx7-1</gtr:outcomeId><gtr:partnerContribution>Provision of unique clinical cohorts

Funding of research fellows</gtr:partnerContribution><gtr:piContribution>PET imaging of patients with schizophrenia and healthy volunteers</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Amsterdam</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>In-SENS</gtr:description><gtr:id>FF4944A6-9A6C-418C-88ED-37493933F917</gtr:id><gtr:impact>Increased cadre of researchers with clinical translation skills</gtr:impact><gtr:outcomeId>ZW2TLo4aGdX-6</gtr:outcomeId><gtr:partnerContribution>Teaching and training and sharing data</gtr:partnerContribution><gtr:piContribution>Teaching and training and sharing data</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Autonomous University of Madrid (UAM)</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>METSY</gtr:description><gtr:id>826F905B-0975-48E5-AC6B-C6F76DEE80EB</gtr:id><gtr:impact>Harmonisation of data collection</gtr:impact><gtr:outcomeId>WhmvjVB8Nd2-2</gtr:outcomeId><gtr:partnerContribution>Sharing data and expertise on analysis</gtr:partnerContribution><gtr:piContribution>Sharing data and collaborating on developing a new diagnostic and predictive biomarker platform for psychosis and metabolic dysfunction</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Psychiatry</gtr:department><gtr:description>Neurobiology of affect regulation-brain-gene (Oxford)</gtr:description><gtr:id>3636BA2F-9C21-4385-AA9C-1702A7D1C6A2</gtr:id><gtr:impact>Publications:

Decreased regional gray matter volume in S' allele carriers of the 5-HTTLPR triallelic polymorphism.
Selvaraj S, Godlewska BR, Norbury R, Bose S, Turkheimer F, Stokes P, Rhodes R, Howes O, Cowen PJ.
Mol Psychiatry. 2010 Nov 2</gtr:impact><gtr:outcomeId>rXXdBAhXxEG-1</gtr:outcomeId><gtr:partnerContribution>Determination of genetic polymorphisms and analysis of data &amp;amp; research fellow support</gtr:partnerContribution><gtr:piContribution>Acquisition and analysis of neuroimaging data</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sylics</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>In-SENS</gtr:description><gtr:id>DC63614F-EEA5-4C76-B729-E83285CDFCAD</gtr:id><gtr:impact>Increased cadre of researchers with clinical translation skills</gtr:impact><gtr:outcomeId>ZW2TLo4aGdX-7</gtr:outcomeId><gtr:partnerContribution>Teaching and training and sharing data</gtr:partnerContribution><gtr:piContribution>Teaching and training and sharing data</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>F. Hoffmann-La Roche AG</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>In-SENS</gtr:description><gtr:id>951E17F0-2071-43B5-A02B-9F65AF8EE78C</gtr:id><gtr:impact>Increased cadre of researchers with clinical translation skills</gtr:impact><gtr:outcomeId>ZW2TLo4aGdX-4</gtr:outcomeId><gtr:partnerContribution>Teaching and training and sharing data</gtr:partnerContribution><gtr:piContribution>Teaching and training and sharing data</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ludwig Maximilian University of Munich (LMU Munich)</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>In-SENS</gtr:description><gtr:id>4F7B687A-14FF-404A-B8E2-4A6132F7979C</gtr:id><gtr:impact>Increased cadre of researchers with clinical translation skills</gtr:impact><gtr:outcomeId>ZW2TLo4aGdX-2</gtr:outcomeId><gtr:partnerContribution>Teaching and training and sharing data</gtr:partnerContribution><gtr:piContribution>Teaching and training and sharing data</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Koninklijke Philips Electronics N.V.</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:department>Philips</gtr:department><gtr:description>METSY</gtr:description><gtr:id>2F45332C-3C1F-4A4E-B309-8915F1B3625F</gtr:id><gtr:impact>Harmonisation of data collection</gtr:impact><gtr:outcomeId>WhmvjVB8Nd2-4</gtr:outcomeId><gtr:partnerContribution>Sharing data and expertise on analysis</gtr:partnerContribution><gtr:piContribution>Sharing data and collaborating on developing a new diagnostic and predictive biomarker platform for psychosis and metabolic dysfunction</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Turku</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>METSY</gtr:description><gtr:id>5195B2AA-3EC8-494F-8643-59F85EF2E97C</gtr:id><gtr:impact>Harmonisation of data collection</gtr:impact><gtr:outcomeId>WhmvjVB8Nd2-3</gtr:outcomeId><gtr:partnerContribution>Sharing data and expertise on analysis</gtr:partnerContribution><gtr:piContribution>Sharing data and collaborating on developing a new diagnostic and predictive biomarker platform for psychosis and metabolic dysfunction</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Media interview</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D6F2271A-DFD0-4B50-883B-AF7F9D47F8FA</gtr:id><gtr:impact>Interviews for BBC and National Geographic TV channels discussing the group's research findings

Viewing figures are reported to be over 1 million for the BBC. The National Geographic broadcast is international as well as UK.</gtr:impact><gtr:outcomeId>aMvEpWM2iNt</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>RCPsych patient &amp; carer education</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BF3D1F2A-4212-4CDD-8620-13AD4432F3DF</gtr:id><gtr:impact>Web cast informing carers and patients about sexual dysfunction in schizophrenia and treatment options.

Patient and carer groups highlighted improved understanding of under-recognised aspect of the condition</gtr:impact><gtr:outcomeId>SiP4vNNCyfv</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Hearts and Minds event</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E3E5B7E8-6B37-4474-88DC-0683837F88F6</gtr:id><gtr:impact>Workshop on our research</gtr:impact><gtr:outcomeId>5899e0b81f9712.47730137</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Central St Martin's College</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>3F41DFFD-0215-4715-BFF9-F950BAB20065</gtr:id><gtr:impact>Presentation to ~80 art students who will develop a project based on this as part of their course work

Students producing art outputs as a result</gtr:impact><gtr:outcomeId>LQtTck8ZpFL</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Patient publication</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>251F3986-1B2B-4626-BBBF-B89218383251</gtr:id><gtr:impact>Article in national patient and carer magazine (readership 50 000+)

Patient and carers contacted me for further information</gtr:impact><gtr:outcomeId>DgXhERndTP2</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>96000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Independent Investigators Scheme (NARSAD)</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Brain &amp; Behaviour Research Foundation</gtr:fundingOrg><gtr:id>811811E2-61A8-4E2F-BC86-046289FB16F7</gtr:id><gtr:outcomeId>pARFrpEJkda</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>16000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Comprehensive Biomedical Research Centre, Guy's and St Thomas</gtr:department><gtr:description>NIHR BRC starter grant (apo)</gtr:description><gtr:end>2013-11-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>482A385D-A650-491C-9DCC-B394C4DDBDAD</gtr:id><gtr:outcomeId>tCQQLgEMF6U</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ECNP</gtr:description><gtr:end>2009-10-02</gtr:end><gtr:fundingOrg>European College of Neuropsychopharmacology (ECNP)</gtr:fundingOrg><gtr:id>AF78EE2D-E1FA-4EB1-AB81-878A4CF72500</gtr:id><gtr:outcomeId>E1AJJ7rBpe90</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2009-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>32000</gtr:amountPounds><gtr:country>Italy, Italian Republic</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Banco di Sardegna Foundation project grant</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Fondazione Banco di Sardegna</gtr:fundingOrg><gtr:id>1BB3B50E-00C5-40E3-9350-0674CAE8115C</gtr:id><gtr:outcomeId>Dwgd24yPyZc</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>330000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>EU Marie-Curie</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>Spanish National Research Council (CSIC)</gtr:fundingOrg><gtr:id>CE4CF9D0-55BA-41F3-B634-D33FB1180A4D</gtr:id><gtr:outcomeId>MmPywWxuHWi</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Sunovion</gtr:department><gtr:description>Sunovion Investigator Initiated Grant</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>Dainippon Sumitomo Pharma?Co</gtr:fundingOrg><gtr:id>5D94F36C-1202-45F5-BBAF-DE59404834A4</gtr:id><gtr:outcomeId>5899df5541ad89.27335394</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2016-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>350000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome</gtr:description><gtr:end>2016-02-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>AA429127-C060-478B-861E-DC6A826C33A6</gtr:id><gtr:outcomeId>cmg6VrdaMWP</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>356554</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Clinical Research Training fellowship</gtr:description><gtr:end>2019-12-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>8AEA60D5-41B7-4EEE-AED7-B3281EE22AFB</gtr:id><gtr:outcomeId>56c66cba8fe9d2.69144461</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3800000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Stratified Medicince</gtr:description><gtr:end>2019-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>47DA0074-638B-4EEE-97AB-7EEE95D4EE49</gtr:id><gtr:outcomeId>fF5AMJ7ahpw</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3838000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>EU FP-7</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>Spanish National Research Council (CSIC)</gtr:fundingOrg><gtr:id>D558EC6C-726E-4485-B326-E65F26E3F738</gtr:id><gtr:outcomeId>LVEcJqCcR5H</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Brain</gtr:description><gtr:end>2009-06-02</gtr:end><gtr:fundingOrg>Guarantors of Brain</gtr:fundingOrg><gtr:id>9273AF2F-0722-4F7A-915A-480213B6078F</gtr:id><gtr:outcomeId>oJtZBVotFya0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1054000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome</gtr:description><gtr:end>2016-10-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>26B4997C-0D11-4C20-9AF8-EF28547BDA5F</gtr:id><gtr:outcomeId>Dz8ZQ7TC4B50</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>297000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Maudsley Charity</gtr:department><gtr:description>Maudsley Charity TREAT Project grant</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>South London and Maudsley (SLAM) NHS Foundation Trust</gtr:fundingOrg><gtr:fundingRef>666</gtr:fundingRef><gtr:id>D2FB59E3-C364-4E03-9CC7-EF7BC66FAFD3</gtr:id><gtr:outcomeId>fGbGgowpmY3</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>340000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>March of Dimes</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>March of Dimes Foundation</gtr:fundingOrg><gtr:id>FA42F6DF-5FA8-496A-A60D-7CA86A611D31</gtr:id><gtr:outcomeId>FqxiDuDawc70</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>350000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC</gtr:description><gtr:end>2010-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>FA424345-358E-4057-9B89-06D1022C1857</gtr:id><gtr:outcomeId>BQSgkyPd8qd0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>72000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Roche investigator initiated grant</gtr:description><gtr:end>2018-04-02</gtr:end><gtr:fundingOrg>F. Hoffmann-La Roche AG</gtr:fundingOrg><gtr:id>625AD6F7-31C0-4803-B004-DC3A26AB704C</gtr:id><gtr:outcomeId>58c7bcabc07352.09410931</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>11000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR</gtr:description><gtr:end>2012-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>B7255FEA-52E4-48B5-A4D2-23A202DAE958</gtr:id><gtr:outcomeId>REArxQWPoyo0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>107771</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>King's India scholarship</gtr:description><gtr:end>2019-05-02</gtr:end><gtr:fundingOrg>King's College London</gtr:fundingOrg><gtr:id>DFF3B05E-7A29-436E-9B85-31F74DD99F60</gtr:id><gtr:outcomeId>56c655c6d40881.67999655</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>22500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Academy of Medical Sciences starter grant (emotion processing CUMI)</gtr:description><gtr:end>2013-06-02</gtr:end><gtr:fundingOrg>Academy of Medical Sciences (AMS)</gtr:fundingOrg><gtr:id>BE7A6230-C705-41B7-8CA7-8627CC3E800D</gtr:id><gtr:outcomeId>WEU7z7m9hL3</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Royal College Schizophrenia Treatment UK Guidelines</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>E8F37B3D-2C33-45E9-9ACD-5E8E746E9D43</gtr:id><gtr:impact>Management guidelines to all UK psychiatrists</gtr:impact><gtr:outcomeId>GcuDYWHJQT5</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>Multivariate image analytic system for diagnosing schizophrenia. The initial evaluation has been published and it is currently under refinement using additional clinical populations to determine its generalisability</gtr:description><gtr:id>2677577F-87E9-45FD-9E65-739155E40A20</gtr:id><gtr:impact>It has provide insights into the pathophysiology of schizophrenia</gtr:impact><gtr:outcomeId>fMFiWUZBnFD</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>PET diagnostic classifier for schizophrenia</gtr:title><gtr:type>Diagnostic Tool - Imaging</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Database of PET imaging data on the dopaminergic and serotinergic systems in healthy volunteers and socio-demographic and psychological indices.</gtr:description><gtr:id>0575182A-6F67-4792-9D60-5ED290FD9678</gtr:id><gtr:impact>This has resulted in a number of publications describing the relationship between socio-demographic (including age, and substance misuse) and personality factors, and is being used by an EU consortium to develop novel approaches to PET image analysis</gtr:impact><gtr:outcomeId>ttLF1iKoN5N</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Database of neurochemical function in healthy volunteers</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E698BC7A-9AF7-4725-94FD-2FDF3A351409</gtr:id><gtr:title>Neuropathological changes in the substantia nigra in schizophrenia but not depression.</gtr:title><gtr:parentPublicationTitle>European archives of psychiatry and clinical neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9991ed98e1526145913295dd0707b39"><gtr:id>e9991ed98e1526145913295dd0707b39</gtr:id><gtr:otherNames>Williams MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0940-1334</gtr:issn><gtr:outcomeId>5461f0362ac909.34495507</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99E245CE-7F29-4C61-B64E-F62B3740333F</gtr:id><gtr:title>Editorial: Reporting guidelines for psychopharmacology.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4eb0da0ce0c3b82bacb89052ab585c1"><gtr:id>a4eb0da0ce0c3b82bacb89052ab585c1</gtr:id><gtr:otherNames>Steckler T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>5899cc269f5653.97090461</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>619C31D9-DB79-4055-931B-A356A8F624EA</gtr:id><gtr:title>Response to Narendran and Frankle: The Interpretation of PET Microglial Imaging in Schizophrenia.</gtr:title><gtr:parentPublicationTitle>The American journal of psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75ca5ea61c140abe28a788ca8941849e"><gtr:id>75ca5ea61c140abe28a788ca8941849e</gtr:id><gtr:otherNames>Bloomfield PS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0002-953X</gtr:issn><gtr:outcomeId>5899c95f8f6607.31330497</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61346D49-42D5-4225-B5A5-FECB75F3CA6F</gtr:id><gtr:title>Further human evidence for striatal dopamine release induced by administration of ?9-tetrahydrocannabinol (THC): selectivity to limbic striatum.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0a4b4fe60da7aac199aa2977416b6eef"><gtr:id>0a4b4fe60da7aac199aa2977416b6eef</gtr:id><gtr:otherNames>Bossong MG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>568fcf029227f2.53243232</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8D8DCC8-4FFA-4F4F-83C5-166868497CC1</gtr:id><gtr:title>Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?</gtr:title><gtr:parentPublicationTitle>The British journal of psychiatry : the journal of mental science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3aa1a9a5f22dc4f696a5505a4e6ea5d4"><gtr:id>3aa1a9a5f22dc4f696a5505a4e6ea5d4</gtr:id><gtr:otherNames>Murray RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0007-1250</gtr:issn><gtr:outcomeId>5899c5e2860528.99528567</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD5BA8B9-EBE2-4AAF-935F-35A05F6233F9</gtr:id><gtr:title>Hyperprolactinaemia in first episode psychosis - A longitudinal assessment.</gtr:title><gtr:parentPublicationTitle>Schizophrenia research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93ea0bb91d90325b6e0539f945e0a739"><gtr:id>93ea0bb91d90325b6e0539f945e0a739</gtr:id><gtr:otherNames>Lally J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0920-9964</gtr:issn><gtr:outcomeId>5a78295621f816.69625130</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF290B3C-6F29-4C9B-A674-3267334FD08D</gtr:id><gtr:title>The impact of Disrupted-in-Schizophrenia 1 (DISC1) on the dopaminergic system: a systematic review.</gtr:title><gtr:parentPublicationTitle>Translational psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f0fcdb0e604f3aca6b426f5c3eb19f30"><gtr:id>f0fcdb0e604f3aca6b426f5c3eb19f30</gtr:id><gtr:otherNames>Dahoun T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2158-3188</gtr:issn><gtr:outcomeId>5899c400e03767.64649506</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5183F3A9-B95F-4384-B906-3E06031F6AD8</gtr:id><gtr:title>Defining the Locus of Dopaminergic Dysfunction in Schizophrenia: A Meta-analysis and Test of the Mesolimbic Hypothesis.</gtr:title><gtr:parentPublicationTitle>Schizophrenia bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02f2dc723bbbb872f25e56b73d41a849"><gtr:id>02f2dc723bbbb872f25e56b73d41a849</gtr:id><gtr:otherNames>McCutcheon R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0586-7614</gtr:issn><gtr:outcomeId>5a781ece198564.10122284</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>179D6A25-3703-4E18-97B5-C2C1DDF14AF2</gtr:id><gtr:title>Microglial Activity in People at Ultra High Risk of Psychosis and in Schizophrenia: An [(11)C]PBR28 PET Brain Imaging Study.</gtr:title><gtr:parentPublicationTitle>The American journal of psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75ca5ea61c140abe28a788ca8941849e"><gtr:id>75ca5ea61c140abe28a788ca8941849e</gtr:id><gtr:otherNames>Bloomfield PS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0002-953X</gtr:issn><gtr:outcomeId>568fceff2bdcf8.82342575</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6069993-6B1C-48F5-A482-144B647B6D86</gtr:id><gtr:title>Resting Hyperperfusion of the Hippocampus, Midbrain, and Basal Ganglia in People at High Risk for Psychosis.</gtr:title><gtr:parentPublicationTitle>The American journal of psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ce4ab107178e3e91d84a742dbaab1870"><gtr:id>ce4ab107178e3e91d84a742dbaab1870</gtr:id><gtr:otherNames>Allen P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0002-953X</gtr:issn><gtr:outcomeId>568fda55aee0f3.43934573</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50FBCD36-831B-4C17-87C6-D90ACCD74981</gtr:id><gtr:title>Kinetic modelling of [C]PBR28 for 18 kDa translocator protein PET data: A validation study of vascular modelling in the brain using XBD173 and tissue analysis.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9af2668d77c8ecdf7e5ae1c6b30b68b5"><gtr:id>9af2668d77c8ecdf7e5ae1c6b30b68b5</gtr:id><gtr:otherNames>Veronese M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn><gtr:outcomeId>5a7829fd74c085.65595208</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD784BFA-B456-4908-9E6E-82B8BF8961B9</gtr:id><gtr:title>Cholesterol and triglyceride levels in first-episode psychosis: systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>The British journal of psychiatry : the journal of mental science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a65bfc1b8abd7d7955764a76ed2fb2a7"><gtr:id>a65bfc1b8abd7d7955764a76ed2fb2a7</gtr:id><gtr:otherNames>Pillinger T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0007-1250</gtr:issn><gtr:outcomeId>5a78219d1292d3.93004552</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>00AD1E3D-869E-4E64-9B14-C3D48F64F020</gtr:id><gtr:title>Characterization of the anterior cingulate's role in the at-risk mental state using graph theory.</gtr:title><gtr:parentPublicationTitle>NeuroImage</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e1ed4e0a05933624d5f58bd3a151da50"><gtr:id>e1ed4e0a05933624d5f58bd3a151da50</gtr:id><gtr:otherNames>Lord LD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1053-8119</gtr:issn><gtr:outcomeId>TDnmvmnYatN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37C1C75C-6BBB-4E28-ABC5-D45A3649B031</gtr:id><gtr:title>Generalization of endothelial modelling of TSPO PET imaging: Considerations on tracer affinities.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f7b3fc52c6cea6e41aeb69c25ad3e6f6"><gtr:id>f7b3fc52c6cea6e41aeb69c25ad3e6f6</gtr:id><gtr:otherNames>Rizzo G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn><gtr:outcomeId>5a78207b7072a3.83643118</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED334D67-B35C-4BDE-BCC0-C9F663D7CD11</gtr:id><gtr:title>Inflammation: its role in schizophrenia and the potential anti-inflammatory effects of antipsychotics.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a34bed4dcc674485c8692e22b0bc3da"><gtr:id>2a34bed4dcc674485c8692e22b0bc3da</gtr:id><gtr:otherNames>Mondelli V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>5461f5285e9c17.42330766</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8223A9E9-B38C-4DC1-A5B3-88E1CCF248FE</gtr:id><gtr:title>Presynaptic Serotoninergic Regulation of Emotional Processing: A Multimodal Brain Imaging Study.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f36a0b46d325daf7d58d5c21cdcf6fda"><gtr:id>f36a0b46d325daf7d58d5c21cdcf6fda</gtr:id><gtr:otherNames>Selvaraj S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>545ce211a4ebd9.45795275</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>73879753-99C9-4D41-9CB8-912CBE3F86A6</gtr:id><gtr:title>Dopamine synthesis capacity in patients with treatment-resistant schizophrenia.</gtr:title><gtr:parentPublicationTitle>The American journal of psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8351ab06ac06ebf444f6bf4346a232c"><gtr:id>b8351ab06ac06ebf444f6bf4346a232c</gtr:id><gtr:otherNames>Demjaha A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0002-953X</gtr:issn><gtr:outcomeId>pm_15289_29_23034655</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6EF154D-3160-4368-AF51-D9BDDD35F6A7</gtr:id><gtr:title>Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b3dfa96a9ff12ea5516b963792374da2"><gtr:id>b3dfa96a9ff12ea5516b963792374da2</gtr:id><gtr:otherNames>Howes O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn><gtr:outcomeId>tvsvwQaFe3d</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>07545C84-3AC5-46FD-836D-5B49520B3ADE</gtr:id><gtr:title>Prevalence of serum N-methyl-D-aspartate receptor autoantibodies in refractory psychosis.</gtr:title><gtr:parentPublicationTitle>The British journal of psychiatry : the journal of mental science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c975fa03eb54774fe421ed0b63329471"><gtr:id>c975fa03eb54774fe421ed0b63329471</gtr:id><gtr:otherNames>Beck K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-1250</gtr:issn><gtr:outcomeId>568fda56561739.68386491</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A04A3E9-E9C9-4DA6-840D-8B804BA130F6</gtr:id><gtr:title>Molecular imaging as a guide for the treatment of central nervous system disorders.</gtr:title><gtr:parentPublicationTitle>Dialogues in clinical neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30b0216384060a4ecdaf9e25a17b961c"><gtr:id>30b0216384060a4ecdaf9e25a17b961c</gtr:id><gtr:otherNames>Kim E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1294-8322</gtr:issn><gtr:outcomeId>5461f528da78b1.32523280</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>389334A2-2335-4BF5-BE60-F93B5B39A1E7</gtr:id><gtr:title>Early detection and intervention in bipolar affective disorder: targeting the development of the disorder.</gtr:title><gtr:parentPublicationTitle>Current psychiatry reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0691a45ce814dfc6ab4c3e6dd94e781"><gtr:id>a0691a45ce814dfc6ab4c3e6dd94e781</gtr:id><gtr:otherNames>Howes OD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1523-3812</gtr:issn><gtr:outcomeId>osgGio1wuHH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE5F30B5-F1C6-4DB7-91EE-3F77B2C938C7</gtr:id><gtr:title>Dopamine transporter imaging: nonindependence of regional measures.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f36a0b46d325daf7d58d5c21cdcf6fda"><gtr:id>f36a0b46d325daf7d58d5c21cdcf6fda</gtr:id><gtr:otherNames>Selvaraj S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn><gtr:outcomeId>545ce2124e2857.22161231</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>892E3EE6-CB97-4626-BDEF-6D4558A64BA0</gtr:id><gtr:title>Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation.</gtr:title><gtr:parentPublicationTitle>The British journal of psychiatry : the journal of mental science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0691a45ce814dfc6ab4c3e6dd94e781"><gtr:id>a0691a45ce814dfc6ab4c3e6dd94e781</gtr:id><gtr:otherNames>Howes OD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-1250</gtr:issn><gtr:outcomeId>pm_15289_29_22955007</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>856E0108-E077-481D-9C6E-A6B0589C5FD4</gtr:id><gtr:title>Is clinical intervention in the ultra high risk phase effective?</gtr:title><gtr:parentPublicationTitle>Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31467d4a8a2dee0bc64957171260598f"><gtr:id>31467d4a8a2dee0bc64957171260598f</gtr:id><gtr:otherNames>McGuire P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1516-4446</gtr:issn><gtr:outcomeId>pm_15289_29_22286566</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CDEF042-B440-4267-9AEB-0797C4D1FD30</gtr:id><gtr:title>Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d291d20ff6b7d57155002e6583fb3ce2"><gtr:id>d291d20ff6b7d57155002e6583fb3ce2</gtr:id><gtr:otherNames>Fusar-Poli P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn><gtr:outcomeId>qbayniaJGHY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6BBD89F3-78D5-4EFD-9F03-BFA213C36210</gtr:id><gtr:title>Elevated Striatal Dopamine Function in Immigrants and Their Children: A Risk Mechanism for Psychosis.</gtr:title><gtr:parentPublicationTitle>Schizophrenia bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a79e5d2d5d5dfbe5a7d92af4cf5c830a"><gtr:id>a79e5d2d5d5dfbe5a7d92af4cf5c830a</gtr:id><gtr:otherNames>Egerton A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0586-7614</gtr:issn><gtr:outcomeId>5899c506580289.36963040</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6E628D3-61ED-4AA3-A381-0ECD96BB02BC</gtr:id><gtr:title>Dopamine function in cigarette smokers: an [&amp;sup1;8F]-DOPA PET study.</gtr:title><gtr:parentPublicationTitle>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/413ae84d0e24f0badbf8a45ff98faf7f"><gtr:id>413ae84d0e24f0badbf8a45ff98faf7f</gtr:id><gtr:otherNames>Bloomfield MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0893-133X</gtr:issn><gtr:outcomeId>545ce25367bc01.01783926</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E290D6E-6E4B-4051-9744-64154BF1EE6F</gtr:id><gtr:title>Autoantibodies to central nervous system neuronal surface antigens: psychiatric symptoms and psychopharmacological implications.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f3f271c872e6312ac7a7971d88879a3"><gtr:id>8f3f271c872e6312ac7a7971d88879a3</gtr:id><gtr:otherNames>Pollak TA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>568fda560b8784.63448388</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2376578B-9C01-4EC8-9481-254B7E6E4C2B</gtr:id><gtr:title>Single cocaine exposure does not alter striatal pre-synaptic dopamine function in mice: an [F]-FDOPA PET study.</gtr:title><gtr:parentPublicationTitle>Journal of neurochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/73024ea5a5bd56d0077a847856a6a484"><gtr:id>73024ea5a5bd56d0077a847856a6a484</gtr:id><gtr:otherNames>Bonsall DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-3042</gtr:issn><gtr:outcomeId>5a782422a6c826.54974802</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8D97168-65BE-4358-A4E2-CD5BBC82CAD1</gtr:id><gtr:title>Salience attribution and its relationship to cannabis-induced psychotic symptoms.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/413ae84d0e24f0badbf8a45ff98faf7f"><gtr:id>413ae84d0e24f0badbf8a45ff98faf7f</gtr:id><gtr:otherNames>Bloomfield MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>5899c7ffca4716.98975229</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C334D11-7026-44CE-A79C-EBF2D4BF0EEB</gtr:id><gtr:title>Dopaminergic function in the psychosis spectrum: an [18F]-DOPA imaging study in healthy individuals with auditory hallucinations.</gtr:title><gtr:parentPublicationTitle>Schizophrenia bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0691a45ce814dfc6ab4c3e6dd94e781"><gtr:id>a0691a45ce814dfc6ab4c3e6dd94e781</gtr:id><gtr:otherNames>Howes OD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0586-7614</gtr:issn><gtr:outcomeId>pm_15289_29_22282457</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F673B3E4-B157-4BFA-AD7D-99FAC6DEFC11</gtr:id><gtr:title>Abnormal relationship between medial temporal lobe and subcortical dopamine function in people with an ultra high risk for psychosis.</gtr:title><gtr:parentPublicationTitle>Schizophrenia bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ce4ab107178e3e91d84a742dbaab1870"><gtr:id>ce4ab107178e3e91d84a742dbaab1870</gtr:id><gtr:otherNames>Allen P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0586-7614</gtr:issn><gtr:outcomeId>jsJpG5tS9gh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6C44662-2D91-44E3-A0F5-472380C32221</gtr:id><gtr:title>Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8351ab06ac06ebf444f6bf4346a232c"><gtr:id>b8351ab06ac06ebf444f6bf4346a232c</gtr:id><gtr:otherNames>Demjaha A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>pm_15289_29_23890739</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7D72C6F-E79A-40C8-85A4-D03849BAE88A</gtr:id><gtr:title>Effects of citalopram on serotonin neurotransmission.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f36a0b46d325daf7d58d5c21cdcf6fda"><gtr:id>f36a0b46d325daf7d58d5c21cdcf6fda</gtr:id><gtr:otherNames>Selvaraj S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn><gtr:outcomeId>pm_15289_29_23168914</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>955FBB52-2A1E-4CAE-A62B-3608573686BE</gtr:id><gtr:title>Transition to psychosis associated with prefrontal and subcortical dysfunction in ultra high-risk individuals.</gtr:title><gtr:parentPublicationTitle>Schizophrenia bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ce4ab107178e3e91d84a742dbaab1870"><gtr:id>ce4ab107178e3e91d84a742dbaab1870</gtr:id><gtr:otherNames>Allen P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0586-7614</gtr:issn><gtr:outcomeId>pm_15289_29_22290265</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E50B9C0-C912-4A51-AF3D-44CF1CCAB006</gtr:id><gtr:title>The Role of Antipsychotic Plasma Levels in the Treatment of Schizophrenia.</gtr:title><gtr:parentPublicationTitle>The American journal of psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b0757d9eebf1a7ba70668368f6fb84bc"><gtr:id>b0757d9eebf1a7ba70668368f6fb84bc</gtr:id><gtr:otherNames>Horvitz-Lennon M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0002-953X</gtr:issn><gtr:outcomeId>5a7829fe33fb91.87351336</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2312B4C2-7341-43FE-A964-E2FF31568052</gtr:id><gtr:title>Striatal dopamine transporter availability in drug-naive patients with schizophrenia: a case-control SPECT study with [(99m)Tc]-TRODAT-1 and a meta-analysis.</gtr:title><gtr:parentPublicationTitle>Schizophrenia bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/23378a6af2fb1c8bb76b6c4f141d1d5a"><gtr:id>23378a6af2fb1c8bb76b6c4f141d1d5a</gtr:id><gtr:otherNames>Chen KC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0586-7614</gtr:issn><gtr:outcomeId>pm_15289_29_22156764</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40AE7BFB-033A-4C67-AF51-305625C6D424</gtr:id><gtr:title>The test-retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function.</gtr:title><gtr:parentPublicationTitle>NeuroImage</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a79e5d2d5d5dfbe5a7d92af4cf5c830a"><gtr:id>a79e5d2d5d5dfbe5a7d92af4cf5c830a</gtr:id><gtr:otherNames>Egerton A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1053-8119</gtr:issn><gtr:outcomeId>efa4Tr5jQkb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BBB08A5E-D98F-4164-8108-F58CB6C243DF</gtr:id><gtr:title>Antipsychotic plasma levels in the assessment of poor treatment response in&amp;nbsp;schizophrenia.</gtr:title><gtr:parentPublicationTitle>Acta psychiatrica Scandinavica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02f2dc723bbbb872f25e56b73d41a849"><gtr:id>02f2dc723bbbb872f25e56b73d41a849</gtr:id><gtr:otherNames>McCutcheon R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0001-690X</gtr:issn><gtr:outcomeId>5a6d8f22c325c7.70631737</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7235C7B5-765A-44EB-8080-00B054162EB1</gtr:id><gtr:title>Functionally defined regions may aid interpretation of striatal dopamine elevation in schizophrenia.</gtr:title><gtr:parentPublicationTitle>Schizophrenia research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a79e5d2d5d5dfbe5a7d92af4cf5c830a"><gtr:id>a79e5d2d5d5dfbe5a7d92af4cf5c830a</gtr:id><gtr:otherNames>Egerton A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0920-9964</gtr:issn><gtr:outcomeId>iTHxtNZLzDn</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B014AD7-3838-410B-A194-C6DE9EC43168</gtr:id><gtr:title>Alterations in the serotonin system in schizophrenia: a systematic review and meta-analysis of postmortem and molecular imaging studies.</gtr:title><gtr:parentPublicationTitle>Neuroscience and biobehavioral reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f36a0b46d325daf7d58d5c21cdcf6fda"><gtr:id>f36a0b46d325daf7d58d5c21cdcf6fda</gtr:id><gtr:otherNames>Selvaraj S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0149-7634</gtr:issn><gtr:outcomeId>545cdfa3d37187.47440613</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B232E4D8-062E-48D0-9DFF-DEA9DAF1F9E1</gtr:id><gtr:title>Functional outcome in people at high risk for psychosis predicted by thalamic glutamate levels and prefronto-striatal activation.</gtr:title><gtr:parentPublicationTitle>Schizophrenia bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ce4ab107178e3e91d84a742dbaab1870"><gtr:id>ce4ab107178e3e91d84a742dbaab1870</gtr:id><gtr:otherNames>Allen P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0586-7614</gtr:issn><gtr:outcomeId>545cdfa33aebe8.88067388</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4AE614F2-56CD-4BD5-8D04-B8B3515F586C</gtr:id><gtr:title>Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study.</gtr:title><gtr:parentPublicationTitle>The American journal of psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0691a45ce814dfc6ab4c3e6dd94e781"><gtr:id>a0691a45ce814dfc6ab4c3e6dd94e781</gtr:id><gtr:otherNames>Howes OD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0002-953X</gtr:issn><gtr:outcomeId>QVZD1ovyvt6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0D93E80-63B6-4A0B-9BB4-3F7539BE23BF</gtr:id><gtr:title>The effects of ?-tetrahydrocannabinol on the dopamine system.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/413ae84d0e24f0badbf8a45ff98faf7f"><gtr:id>413ae84d0e24f0badbf8a45ff98faf7f</gtr:id><gtr:otherNames>Bloomfield MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>5899c5e25cedb4.27404771</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4569272-8CBF-41DB-8889-37DB7117153B</gtr:id><gtr:title>Stress and neuroinflammation: a systematic review of the effects of stress on microglia and the implications for mental illness.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/474344aaf9b4cbfbc90ec427186bd3ba"><gtr:id>474344aaf9b4cbfbc90ec427186bd3ba</gtr:id><gtr:otherNames>Calcia MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>5899cd125653b4.92496942</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24F29DFA-B094-4C0A-8961-23AFF2C4AF57</gtr:id><gtr:title>The importance of venous thromboembolism - a physical consequence of psychiatric treatments.</gtr:title><gtr:parentPublicationTitle>International journal of clinical practice</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e817fdf53a7006e5a0843dba76924493"><gtr:id>e817fdf53a7006e5a0843dba76924493</gtr:id><gtr:otherNames>Stansby G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1368-5031</gtr:issn><gtr:outcomeId>E4CEUq1jjyr</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D90DD40D-5A1D-4BAA-BBC5-1D95B4B7FA6C</gtr:id><gtr:title>Phosphodiesterase 10A in Schizophrenia: A PET Study Using [(11)C]IMA107.</gtr:title><gtr:parentPublicationTitle>The American journal of psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1f97baa8e5ebb1e342f4eaf589b393a"><gtr:id>b1f97baa8e5ebb1e342f4eaf589b393a</gtr:id><gtr:otherNames>Marques TR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0002-953X</gtr:issn><gtr:outcomeId>5899cc26bff9d1.03376988</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24FEB2DC-1CAA-48CB-B3B5-6D5FDFA880DA</gtr:id><gtr:title>The methodology of TSPO imaging with positron emission tomography.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6388bd935e8af8c0bb4d3186f2a3278a"><gtr:id>6388bd935e8af8c0bb4d3186f2a3278a</gtr:id><gtr:otherNames>Turkheimer FE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>568fcefc9056b0.98526848</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC91C5B0-4AE1-4B60-B414-69A00785EB82</gtr:id><gtr:title>Test-retest reproducibility of cannabinoid-receptor type 1 availability quantified with the PET ligand [&amp;sup1;&amp;sup1;C]MePPEP.</gtr:title><gtr:parentPublicationTitle>NeuroImage</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e18ed6830ef0bda04ab664550f014ef"><gtr:id>0e18ed6830ef0bda04ab664550f014ef</gtr:id><gtr:otherNames>Ria?o Barros DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1053-8119</gtr:issn><gtr:outcomeId>545ce211cd4e53.76729521</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F398D31E-D735-4708-9117-31918E2ABD5B</gtr:id><gtr:title>Prevalence and implications of Truman symptoms in subjects at ultra high risk for psychosis.</gtr:title><gtr:parentPublicationTitle>Psychiatry research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8092af9357f7f3cc5c0ccb6e108dc7d2"><gtr:id>8092af9357f7f3cc5c0ccb6e108dc7d2</gtr:id><gtr:otherNames>Madeira L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0165-1781</gtr:issn><gtr:outcomeId>5899ca2b520e16.03798588</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6182EFC4-8B8F-42B1-A349-101F965D5462</gtr:id><gtr:title>Immune influences on the brain: new findings and implications for treatment.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb946697bc0f9579fb05719e815034d2"><gtr:id>bb946697bc0f9579fb05719e815034d2</gtr:id><gtr:otherNames>Duka T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>5899ca2bab0b11.72325674</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F617811-FB58-4C7E-ABBD-F46294F68AC7</gtr:id><gtr:title>The use of healthy volunteers instead of patients to inform drug dosing studies: a [&amp;sup1;&amp;sup1;C]raclopride PET study.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30b0216384060a4ecdaf9e25a17b961c"><gtr:id>30b0216384060a4ecdaf9e25a17b961c</gtr:id><gtr:otherNames>Kim E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>khXiNpM9hT7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A6ACE0D-EC6A-4061-AAFF-422790535DBD</gtr:id><gtr:title>Nature or nurture? Determining the heritability of human striatal dopamine function: an [18F]-DOPA PET study.</gtr:title><gtr:parentPublicationTitle>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ef610bf70a2414f028fadc10f8091b2"><gtr:id>9ef610bf70a2414f028fadc10f8091b2</gtr:id><gtr:otherNames>Stokes PR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0893-133X</gtr:issn><gtr:outcomeId>pm_15289_29_23093224</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DFEDF115-2425-4887-9301-E97EF88B1A3B</gtr:id><gtr:title>Partial volume correction using structural-functional synergistic resolution recovery: comparison with geometric transfer matrix method.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30b0216384060a4ecdaf9e25a17b961c"><gtr:id>30b0216384060a4ecdaf9e25a17b961c</gtr:id><gtr:otherNames>Kim E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn><gtr:outcomeId>pm_15289_29_23486292</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01FFBFF8-5835-40D9-8944-2A16D250C16D</gtr:id><gtr:title>Spatial working memory ability in individuals at ultra high risk for psychosis.</gtr:title><gtr:parentPublicationTitle>Journal of psychiatric research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/803c0b7543709efec105d76eb0a4718b"><gtr:id>803c0b7543709efec105d76eb0a4718b</gtr:id><gtr:otherNames>Goghari VM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-3956</gtr:issn><gtr:outcomeId>pm_540e183e1833e9636</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D7F02204-2268-4F56-BD13-E91A9035B413</gtr:id><gtr:title>Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.</gtr:title><gtr:parentPublicationTitle>The American journal of psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0691a45ce814dfc6ab4c3e6dd94e781"><gtr:id>a0691a45ce814dfc6ab4c3e6dd94e781</gtr:id><gtr:otherNames>Howes OD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0002-953X</gtr:issn><gtr:outcomeId>5899c50526c308.27077173</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>230FD1B4-91B5-460C-99EC-9DB575F947A9</gtr:id><gtr:title>Midbrain dopamine function in schizophrenia and depression: a post-mortem and positron emission tomographic imaging study.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0691a45ce814dfc6ab4c3e6dd94e781"><gtr:id>a0691a45ce814dfc6ab4c3e6dd94e781</gtr:id><gtr:otherNames>Howes OD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_15289_29_24097339</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41AFF57B-4856-4839-8C39-C00AE9AF9924</gtr:id><gtr:title>Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49b1a2224b337a1dda5d402fdfa5fb51"><gtr:id>49b1a2224b337a1dda5d402fdfa5fb51</gtr:id><gtr:otherNames>Stone JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>SnPBqaM6RKi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22FD4684-67A0-478F-B6FB-3F39519E8A23</gtr:id><gtr:title>Relationship between brain glutamate levels and clinical outcome in individuals at ultra high risk of psychosis.</gtr:title><gtr:parentPublicationTitle>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a79e5d2d5d5dfbe5a7d92af4cf5c830a"><gtr:id>a79e5d2d5d5dfbe5a7d92af4cf5c830a</gtr:id><gtr:otherNames>Egerton A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0893-133X</gtr:issn><gtr:outcomeId>545ce211749860.29507432</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C90DC90-BF03-4C03-A10D-5978FE7161E7</gtr:id><gtr:title>Economic impact of early detection and early intervention of psychosis.</gtr:title><gtr:parentPublicationTitle>Current pharmaceutical design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e1fc6c7dc741f17d75379b1a09057d24"><gtr:id>e1fc6c7dc741f17d75379b1a09057d24</gtr:id><gtr:otherNames>Valmaggia LR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1381-6128</gtr:issn><gtr:outcomeId>pm_15289_29_22239592</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>017F9767-2A39-41EC-86D9-880A23EC2EA1</gtr:id><gtr:title>The relationship between antipsychotic D2 occupancy and change in frontal metabolism and working memory : A dual [(11)C]raclopride and [(18) F]FDG imaging study with aripiprazole.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30b0216384060a4ecdaf9e25a17b961c"><gtr:id>30b0216384060a4ecdaf9e25a17b961c</gtr:id><gtr:otherNames>Kim E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>pm_15289_29_23271192</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>03893078-BD9D-45D8-8C89-4B0D13B41391</gtr:id><gtr:title>Clinical correlates of vitamin D deficiency in established psychosis.</gtr:title><gtr:parentPublicationTitle>BMC psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93ea0bb91d90325b6e0539f945e0a739"><gtr:id>93ea0bb91d90325b6e0539f945e0a739</gtr:id><gtr:otherNames>Lally J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-244X</gtr:issn><gtr:outcomeId>5899ca2bd83a86.31236831</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89954204-9B21-4284-ADF3-0F5DBDB2BBAE</gtr:id><gtr:title>Presynaptic 5-HT1A is related to 5-HTT receptor density in the human brain.</gtr:title><gtr:parentPublicationTitle>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/feaee50a346b08e03393701e3a61b837"><gtr:id>feaee50a346b08e03393701e3a61b837</gtr:id><gtr:otherNames>Bose SK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0893-133X</gtr:issn><gtr:outcomeId>rx6U59eCGtQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E8212F68-E1E6-4D5F-822C-3DEE6E104720</gtr:id><gtr:title>Glutamate and dopamine in schizophrenia: an update for the 21st century.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b3dfa96a9ff12ea5516b963792374da2"><gtr:id>b3dfa96a9ff12ea5516b963792374da2</gtr:id><gtr:otherNames>Howes O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>5899cf3bb22b66.35182829</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C89E5EDD-9B0B-475E-9B4F-8B352CA6C5EC</gtr:id><gtr:title>The nature of dopamine dysfunction in schizophrenia and what this means for treatment.</gtr:title><gtr:parentPublicationTitle>Archives of general psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0691a45ce814dfc6ab4c3e6dd94e781"><gtr:id>a0691a45ce814dfc6ab4c3e6dd94e781</gtr:id><gtr:otherNames>Howes OD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0003-990X</gtr:issn><gtr:outcomeId>pm_15289_29_22474070</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6214DF62-3FE6-418D-9BE6-25EF9512E978</gtr:id><gtr:title>Abnormal frontostriatal interactions in people with prodromal signs of psychosis: a multimodal imaging study.</gtr:title><gtr:parentPublicationTitle>Archives of general psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d291d20ff6b7d57155002e6583fb3ce2"><gtr:id>d291d20ff6b7d57155002e6583fb3ce2</gtr:id><gtr:otherNames>Fusar-Poli P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0003-990X</gtr:issn><gtr:outcomeId>mhuWiNEPJXY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ABD119E8-2A37-4722-9298-61D74C1DF62E</gtr:id><gtr:title>Associative blocking to reward-predicting cues is attenuated in ketamine users but can be modulated by images associated with drug use.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e4ad1a624540e3dfb13ba77aa179d8c"><gtr:id>8e4ad1a624540e3dfb13ba77aa179d8c</gtr:id><gtr:otherNames>Freeman TP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>pm_15289_29_22829431</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3FD1BBEE-3225-41E0-B942-146B711F19E6</gtr:id><gtr:title>Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02f2dc723bbbb872f25e56b73d41a849"><gtr:id>02f2dc723bbbb872f25e56b73d41a849</gtr:id><gtr:otherNames>McCutcheon R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>568fcf05037a37.05712139</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>724FB685-AEE2-4E5E-9F03-3AC1C6C07408</gtr:id><gtr:title>Mind the mortality gap: the importance of metabolic function in mental illnesses.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0691a45ce814dfc6ab4c3e6dd94e781"><gtr:id>a0691a45ce814dfc6ab4c3e6dd94e781</gtr:id><gtr:otherNames>Howes OD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>pm_15289_29_24005530</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>832BCC52-7083-4D57-AE76-8BDF1CEC0AC6</gtr:id><gtr:title>Predicting brain occupancy from plasma levels using PET: superiority of combining pharmacokinetics with pharmacodynamics while modeling the relationship.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30b0216384060a4ecdaf9e25a17b961c"><gtr:id>30b0216384060a4ecdaf9e25a17b961c</gtr:id><gtr:otherNames>Kim E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn><gtr:outcomeId>pm_15289_29_22186667</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6EBAFC54-383D-4466-8741-F4E7DE4196DF</gtr:id><gtr:title>Targeting glutamate to treat schizophrenia: lessons from recent clinical studies.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c975fa03eb54774fe421ed0b63329471"><gtr:id>c975fa03eb54774fe421ed0b63329471</gtr:id><gtr:otherNames>Beck K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>5899c95f316d55.56483318</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69129290-AEFD-4633-926A-868D5BDA95B9</gtr:id><gtr:title>Measuring endogenous changes in serotonergic neurotransmission in humans: a [11C]CUMI-101 PET challenge study.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f36a0b46d325daf7d58d5c21cdcf6fda"><gtr:id>f36a0b46d325daf7d58d5c21cdcf6fda</gtr:id><gtr:otherNames>Selvaraj S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn><gtr:outcomeId>pm_15289_29_22665264</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1065E120-0A47-43C6-A86C-ED2CA1826800</gtr:id><gtr:title>Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [F]DOPA PET Study.</gtr:title><gtr:parentPublicationTitle>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30b0216384060a4ecdaf9e25a17b961c"><gtr:id>30b0216384060a4ecdaf9e25a17b961c</gtr:id><gtr:otherNames>Kim E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0893-133X</gtr:issn><gtr:outcomeId>5899c5e22c8917.55758495</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E775913-290B-4DEE-8B03-E1B10A81B231</gtr:id><gtr:title>Does human presynaptic striatal dopamine function predict social conformity?</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ef610bf70a2414f028fadc10f8091b2"><gtr:id>9ef610bf70a2414f028fadc10f8091b2</gtr:id><gtr:otherNames>Stokes PR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>5461f528b11485.54088090</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F989C296-DCFB-4939-819D-6AEC4A2740A4</gtr:id><gtr:title>Interpersonal sensitivity in the at-risk mental state for psychosis.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d678d3f22989b44d649c5c9961f77eae"><gtr:id>d678d3f22989b44d649c5c9961f77eae</gtr:id><gtr:otherNames>Masillo A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>pm_15289_29_22225783</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>011E9626-DF63-4BC4-8E29-595FDA1D09DF</gtr:id><gtr:title>The brain GABA-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: a pilot [(11)C]Ro15-4513 positron emission tomography study.</gtr:title><gtr:parentPublicationTitle>Neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a84a97df2a89df202c0c974f8cd7532"><gtr:id>4a84a97df2a89df202c0c974f8cd7532</gtr:id><gtr:otherNames>Mendez MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3908</gtr:issn><gtr:outcomeId>pm_15289_29_22546616</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86ADD25F-A6AC-44F3-983A-EE46C0430050</gtr:id><gtr:title>Antipsychotic drugs for prevention of relapse.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af09b1af6bba454035877ef677af72c3"><gtr:id>af09b1af6bba454035877ef677af72c3</gtr:id><gtr:otherNames>van Os J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>pm_15289_29_22560608</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>440AEF8D-40D0-46AE-A37A-69AC762BC1BC</gtr:id><gtr:title>Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/413ae84d0e24f0badbf8a45ff98faf7f"><gtr:id>413ae84d0e24f0badbf8a45ff98faf7f</gtr:id><gtr:otherNames>Bloomfield MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>pm_15289_29_23820822</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>901C4B31-481B-4D20-ACC0-657DCF5343C6</gtr:id><gtr:title>The predictive power of brain mRNA mappings for in vivo protein density: a positron emission tomography correlation study.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f7b3fc52c6cea6e41aeb69c25ad3e6f6"><gtr:id>f7b3fc52c6cea6e41aeb69c25ad3e6f6</gtr:id><gtr:otherNames>Rizzo G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn><gtr:outcomeId>545ce21273ada3.56255627</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C58A3656-F91C-4F07-ADD4-E9A3D5525070</gtr:id><gtr:title>Cognitive functioning in prodromal psychosis: a meta-analysis.</gtr:title><gtr:parentPublicationTitle>Archives of general psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d291d20ff6b7d57155002e6583fb3ce2"><gtr:id>d291d20ff6b7d57155002e6583fb3ce2</gtr:id><gtr:otherNames>Fusar-Poli P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0003-990X</gtr:issn><gtr:outcomeId>pm_15289_29_22664547</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>39EC08EB-AAAF-4060-97CF-ADDFD8DE2097</gtr:id><gtr:title>Johann Cristian Reil on the 200th anniversary of the first description of the insula (1809).</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d291d20ff6b7d57155002e6583fb3ce2"><gtr:id>d291d20ff6b7d57155002e6583fb3ce2</gtr:id><gtr:otherNames>Fusar-Poli P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>roe8bJLBjQm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3B1F17BB-F08F-4FFA-86EC-01F1E8435721</gtr:id><gtr:title>Long-Term Heavy Ketamine Use is Associated with Spatial Memory Impairment and Altered Hippocampal Activation.</gtr:title><gtr:parentPublicationTitle>Frontiers in psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/014e80c626f6bbc9f4b2ef77f7209d6d"><gtr:id>014e80c626f6bbc9f4b2ef77f7209d6d</gtr:id><gtr:otherNames>Morgan CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1664-0640</gtr:issn><gtr:outcomeId>5899cf3d097f41.27608279</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C447DF60-1F17-4A44-AC5F-61C37450748A</gtr:id><gtr:title>An initial investigation of abnormal bodily phenomena in subjects at ultra high risk for psychosis: Their prevalence and clinical implications.</gtr:title><gtr:parentPublicationTitle>Comprehensive psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8092af9357f7f3cc5c0ccb6e108dc7d2"><gtr:id>8092af9357f7f3cc5c0ccb6e108dc7d2</gtr:id><gtr:otherNames>Madeira L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0010-440X</gtr:issn><gtr:outcomeId>5899ca2c13f240.48242678</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9DFE4FC3-7627-4DEB-AF92-86DF921DEDC0</gtr:id><gtr:title>The effect of perinatal brain injury on dopaminergic function and hippocampal volume in adult life.</gtr:title><gtr:parentPublicationTitle>eLife</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f9f33415b3c9798b32738ff5723c8d94"><gtr:id>f9f33415b3c9798b32738ff5723c8d94</gtr:id><gtr:otherNames>Froudist-Walsh S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2050-084X</gtr:issn><gtr:outcomeId>5a782036cccc14.36273752</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EBA0E6BA-0081-4A3E-8BBB-210A01B4E69C</gtr:id><gtr:title>Further evaluation of the carbon11-labeled D(2/3) agonist PET radiotracer PHNO: reproducibility in tracer characteristics and characterization of extrastriatal binding.</gtr:title><gtr:parentPublicationTitle>Synapse (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a79e5d2d5d5dfbe5a7d92af4cf5c830a"><gtr:id>a79e5d2d5d5dfbe5a7d92af4cf5c830a</gtr:id><gtr:otherNames>Egerton A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0887-4476</gtr:issn><gtr:outcomeId>PCbqcGtpX6v</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1636FEF4-D386-4438-9158-0F026F279DE9</gtr:id><gtr:title>Schizophrenia: an integrated sociodevelopmental-cognitive model.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0691a45ce814dfc6ab4c3e6dd94e781"><gtr:id>a0691a45ce814dfc6ab4c3e6dd94e781</gtr:id><gtr:otherNames>Howes OD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>pm_540e183e18332ba52</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA5CEB86-A9B9-4E1D-A7BF-16F5F178701E</gtr:id><gtr:title>Pharmacoterrorism: the potential role of psychoactive drugs in the Paris and Tunisian attacks.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e36d1f10469ff9a8db946ab0d17e01a"><gtr:id>9e36d1f10469ff9a8db946ab0d17e01a</gtr:id><gtr:otherNames>Fond G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>5899cd12999545.37692736</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6829D098-9F44-486A-934D-B224333CEB52</gtr:id><gtr:title>Treatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate Cortex Glutamate Compared to Treatment-Responsive.</gtr:title><gtr:parentPublicationTitle>Schizophrenia bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a21171759e684b9c867ad92deb68c78c"><gtr:id>a21171759e684b9c867ad92deb68c78c</gtr:id><gtr:otherNames>Mouchlianitis E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0586-7614</gtr:issn><gtr:outcomeId>568fda55d48111.59937755</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E98909A-B9EC-4DBC-84C1-875A547F666C</gtr:id><gtr:title>The effect of ageing on grey and white matter reductions in schizophrenia.</gtr:title><gtr:parentPublicationTitle>Schizophrenia research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/feaee50a346b08e03393701e3a61b837"><gtr:id>feaee50a346b08e03393701e3a61b837</gtr:id><gtr:otherNames>Bose SK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0920-9964</gtr:issn><gtr:outcomeId>nHBvzwHWxbJ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E4931EDF-941D-44B1-957A-F0A239E3F30F</gtr:id><gtr:title>Interpreting the neurodevelopmental hypothesis of schizophrenia in the context of normal brain development and ageing.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/80f3e3d365c969b880b1172e155a5dde"><gtr:id>80f3e3d365c969b880b1172e155a5dde</gtr:id><gtr:otherNames>Nour MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>568fcf02679162.41478255</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18A40894-F8D0-49BE-9044-F8276AEFF1D5</gtr:id><gtr:title>Decreased regional gray matter volume in S' allele carriers of the 5-HTTLPR triallelic polymorphism.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f36a0b46d325daf7d58d5c21cdcf6fda"><gtr:id>f36a0b46d325daf7d58d5c21cdcf6fda</gtr:id><gtr:otherNames>Selvaraj S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn><gtr:outcomeId>iFFQoxPVxdT</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D31B5EFD-2E8F-4028-B241-59E7BF397DDF</gtr:id><gtr:title>Opposite effects of catechol-O-methyltransferase Val158Met on cortical function in healthy subjects and patients with schizophrenia.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3aea45aefbb5dda8a32e10fc640870c"><gtr:id>e3aea45aefbb5dda8a32e10fc640870c</gtr:id><gtr:otherNames>Prata DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>Z381u5wfoGZ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34D6A8B1-E18F-4F75-9DEF-B9ACFD5A3437</gtr:id><gtr:title>Glutamate, N-acetyl aspartate and psychotic symptoms in chronic ketamine users.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49b1a2224b337a1dda5d402fdfa5fb51"><gtr:id>49b1a2224b337a1dda5d402fdfa5fb51</gtr:id><gtr:otherNames>Stone JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>5461f52884acc4.81161484</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9641F2F4-775D-428C-8B2B-A78D67AC9C95</gtr:id><gtr:title>Impaired Glucose Homeostasis in First-Episode Schizophrenia: A Systematic Review and Meta-analysis.</gtr:title><gtr:parentPublicationTitle>JAMA psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a65bfc1b8abd7d7955764a76ed2fb2a7"><gtr:id>a65bfc1b8abd7d7955764a76ed2fb2a7</gtr:id><gtr:otherNames>Pillinger T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2168-622X</gtr:issn><gtr:outcomeId>5899c3bd0db839.01402292</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B849CA5-BB0C-4A39-82A4-A0B0E96EAC35</gtr:id><gtr:title>Cannabis use and transition to psychosis in people at ultra-high risk.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e1fc6c7dc741f17d75379b1a09057d24"><gtr:id>e1fc6c7dc741f17d75379b1a09057d24</gtr:id><gtr:otherNames>Valmaggia LR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>545cdfa35f5e34.12044571</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>687890E6-C776-4F86-82B2-5B7A4B4CFBB8</gtr:id><gtr:title>Consistent biological findings in major depression: Results from serotonin transporter meta-analyses.</gtr:title><gtr:parentPublicationTitle>Journal of affective disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4b41334629001f83efe0d0b2f5c2da2d"><gtr:id>4b41334629001f83efe0d0b2f5c2da2d</gtr:id><gtr:otherNames>Kambeitz J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0165-0327</gtr:issn><gtr:outcomeId>5899c95fc355c2.01626224</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F1C22FE7-A057-4228-96D7-3F33241F63DA</gtr:id><gtr:title>HPA-axis function and grey matter volume reductions: imaging the diathesis-stress model in individuals at ultra-high risk of psychosis.</gtr:title><gtr:parentPublicationTitle>Translational psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f919d9d0877818a50c27b63a222b581"><gtr:id>8f919d9d0877818a50c27b63a222b581</gtr:id><gtr:otherNames>Valli I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2158-3188</gtr:issn><gtr:outcomeId>5899c95f658624.15649149</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>857398F8-A10E-4BDA-9065-B6A889503DC1</gtr:id><gtr:title>Brain-imaging studies of treatment-resistant schizophrenia: a systematic review.</gtr:title><gtr:parentPublicationTitle>The lancet. Psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a21171759e684b9c867ad92deb68c78c"><gtr:id>a21171759e684b9c867ad92deb68c78c</gtr:id><gtr:otherNames>Mouchlianitis E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2215-0366</gtr:issn><gtr:outcomeId>5899cc26481703.07536437</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B5A8489-F7BC-4A91-B6DA-602D2EBEAEEE</gtr:id><gtr:title>Higher serotonin transporter availability in early-onset obsessive-compulsive disorder patients undergoing escitalopram treatment: A [C]DASB PET study.</gtr:title><gtr:parentPublicationTitle>Human psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f3b0d1be17ddd4dddfaf7d483017db4"><gtr:id>6f3b0d1be17ddd4dddfaf7d483017db4</gtr:id><gtr:otherNames>Lee J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0885-6222</gtr:issn><gtr:outcomeId>5a781fef2f3cd0.14368333</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>937A68D7-14A0-41B4-A51D-CAC073572784</gtr:id><gtr:title>Regulation of dopaminergic function: an [F]-DOPA PET apomorphine challenge study in humans.</gtr:title><gtr:parentPublicationTitle>Translational psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a84d5164320bf6da1e277517de582069"><gtr:id>a84d5164320bf6da1e277517de582069</gtr:id><gtr:otherNames>Jauhar S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2158-3188</gtr:issn><gtr:outcomeId>5a782a855e2630.07020109</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1968944C-E566-40FC-8B66-8E2D9087622D</gtr:id><gtr:title>Delusional ideation, manic symptomatology and working memory in a cohort at clinical high-risk for psychosis: a longitudinal study.</gtr:title><gtr:parentPublicationTitle>European psychiatry : the journal of the Association of European Psychiatrists</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/514dd09c923c86175a39cc1ba3e243f0"><gtr:id>514dd09c923c86175a39cc1ba3e243f0</gtr:id><gtr:otherNames>Broome MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0924-9338</gtr:issn><gtr:outcomeId>FnEARHNNhzT</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1EDC5B10-BD3D-4284-B950-06E851BBCAAD</gtr:id><gtr:title>30 Years on: How the Neurodevelopmental Hypothesis of Schizophrenia Morphed Into the Developmental Risk Factor Model of Psychosis.</gtr:title><gtr:parentPublicationTitle>Schizophrenia bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3aa1a9a5f22dc4f696a5505a4e6ea5d4"><gtr:id>3aa1a9a5f22dc4f696a5505a4e6ea5d4</gtr:id><gtr:otherNames>Murray RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0586-7614</gtr:issn><gtr:outcomeId>5a7821d607ac23.73987418</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>83FB1143-9E4B-472C-ACC9-6302BF454A54</gtr:id><gtr:title>The practical management of refractory schizophrenia--the Maudsley Treatment REview and Assessment Team service approach.</gtr:title><gtr:parentPublicationTitle>Acta psychiatrica Scandinavica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c975fa03eb54774fe421ed0b63329471"><gtr:id>c975fa03eb54774fe421ed0b63329471</gtr:id><gtr:otherNames>Beck K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0001-690X</gtr:issn><gtr:outcomeId>545cdfa30d19b9.71919368</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7634B612-A990-44B9-A066-3B1FAD1768A4</gtr:id><gtr:title>Sensory gating deficits in the attenuated psychosis syndrome.</gtr:title><gtr:parentPublicationTitle>Schizophrenia research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af50a386b662467f252f056120383a71"><gtr:id>af50a386b662467f252f056120383a71</gtr:id><gtr:otherNames>Shaikh M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0920-9964</gtr:issn><gtr:outcomeId>5899cf3bd9b339.05725680</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B0F5C9B-2433-448D-9EAB-5F00B9892744</gtr:id><gtr:title>Very Early Brain Damage Leads to Remodeling of the Working Memory System in Adulthood: A Combined fMRI/Tractography Study.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f9f33415b3c9798b32738ff5723c8d94"><gtr:id>f9f33415b3c9798b32738ff5723c8d94</gtr:id><gtr:otherNames>Froudist-Walsh S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>5899cdaeb61364.68255070</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF0CA839-241D-45B4-8BDD-9DC6D9DFAD08</gtr:id><gtr:title>Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.</gtr:title><gtr:parentPublicationTitle>Current pharmaceutical design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0691a45ce814dfc6ab4c3e6dd94e781"><gtr:id>a0691a45ce814dfc6ab4c3e6dd94e781</gtr:id><gtr:otherNames>Howes OD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1381-6128</gtr:issn><gtr:outcomeId>jVzz1NSmGCv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>52865F36-5987-4832-9005-427FAC296C44</gtr:id><gtr:title>Increased Resting Hippocampal and Basal Ganglia Perfusion in People at Ultra High Risk for Psychosis: Replication in a Second Cohort.</gtr:title><gtr:parentPublicationTitle>Schizophrenia bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ce4ab107178e3e91d84a742dbaab1870"><gtr:id>ce4ab107178e3e91d84a742dbaab1870</gtr:id><gtr:otherNames>Allen P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0586-7614</gtr:issn><gtr:outcomeId>5a781f19a12b67.57504692</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12680D64-FB11-40C8-9AFD-99E634D40423</gtr:id><gtr:title>Authors' reply.</gtr:title><gtr:parentPublicationTitle>The British journal of psychiatry : the journal of mental science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0691a45ce814dfc6ab4c3e6dd94e781"><gtr:id>a0691a45ce814dfc6ab4c3e6dd94e781</gtr:id><gtr:otherNames>Howes OD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-1250</gtr:issn><gtr:outcomeId>pm_15289_29_23869033</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2F5A8F1-9DF1-4281-A056-96E66D43CB55</gtr:id><gtr:title>Longitudinal alterations in motivational salience processing in ultra-high-risk subjects for psychosis.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7455e4a297544a4196a4622617e2e7e1"><gtr:id>7455e4a297544a4196a4622617e2e7e1</gtr:id><gtr:otherNames>Schmidt A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>5899c8006bc092.27875799</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1440996-5321-4C43-B7A0-CEA3D5B115C3</gtr:id><gtr:title>The dopaminergic basis of human behaviors: A review of molecular imaging studies.</gtr:title><gtr:parentPublicationTitle>Neuroscience and biobehavioral reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a79e5d2d5d5dfbe5a7d92af4cf5c830a"><gtr:id>a79e5d2d5d5dfbe5a7d92af4cf5c830a</gtr:id><gtr:otherNames>Egerton A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0149-7634</gtr:issn><gtr:outcomeId>SFhUsTdsqpL</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3557C4B-F50D-40C0-A0DB-26D4979FFA55</gtr:id><gtr:title>Neural and behavioral correlates of aberrant salience in individuals at risk for psychosis.</gtr:title><gtr:parentPublicationTitle>Schizophrenia bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0980c02bfccd40546661ada4b20eaaa1"><gtr:id>0980c02bfccd40546661ada4b20eaaa1</gtr:id><gtr:otherNames>Roiser JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0586-7614</gtr:issn><gtr:outcomeId>pm_15289_29_23236077</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D289714E-5D15-4ECA-A9DC-C4E54546C851</gtr:id><gtr:title>The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0691a45ce814dfc6ab4c3e6dd94e781"><gtr:id>a0691a45ce814dfc6ab4c3e6dd94e781</gtr:id><gtr:otherNames>Howes OD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>5899c5e2d4d762.84925367</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B728C9E-04FE-482F-BB4D-3E693E5888D6</gtr:id><gtr:title>Calculating occupancy when one does not have baseline: a comparison of different options.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30b0216384060a4ecdaf9e25a17b961c"><gtr:id>30b0216384060a4ecdaf9e25a17b961c</gtr:id><gtr:otherNames>Kim E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn><gtr:outcomeId>TQGNSYLJvUs</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F42C528-47E1-45B5-AB61-EB1118388DCC</gtr:id><gtr:title>Translation and cross-cultural adaptation of the Sexual Function Questionnaire (SFQ) into Brazilian Portuguese.</gtr:title><gtr:parentPublicationTitle>Trends in psychiatry and psychotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1449e1da36725db585a6cfe4d24d3848"><gtr:id>1449e1da36725db585a6cfe4d24d3848</gtr:id><gtr:otherNames>Lapa CO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2237-6089</gtr:issn><gtr:outcomeId>5a782956442768.76993240</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FCF032B0-A825-40AA-90C0-9809B3881945</gtr:id><gtr:title>Brain TSPO imaging and gray matter volume in schizophrenia patients and in people at ultra high risk of psychosis: An [C]PBR28 study.</gtr:title><gtr:parentPublicationTitle>Schizophrenia research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f36a0b46d325daf7d58d5c21cdcf6fda"><gtr:id>f36a0b46d325daf7d58d5c21cdcf6fda</gtr:id><gtr:otherNames>Selvaraj S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0920-9964</gtr:issn><gtr:outcomeId>5a782422cfba72.35584797</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91C364DE-3683-4D1A-917E-AEC807069E93</gtr:id><gtr:title>The link between dopamine function and apathy in cannabis users: an [18F]-DOPA PET imaging study.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/413ae84d0e24f0badbf8a45ff98faf7f"><gtr:id>413ae84d0e24f0badbf8a45ff98faf7f</gtr:id><gtr:otherNames>Bloomfield MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>545ce212011151.86798228</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>14615683-2194-42DA-8DFC-66EE388BFB4E</gtr:id><gtr:title>Vitamin D deficiency in first episode psychosis: a case-control study.</gtr:title><gtr:parentPublicationTitle>Schizophrenia research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb2f52d85ac1bc2b75e0ca4600b95ee4"><gtr:id>fb2f52d85ac1bc2b75e0ca4600b95ee4</gtr:id><gtr:otherNames>Crews M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0920-9964</gtr:issn><gtr:outcomeId>pm_15289_29_24060571</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C55E0DD-C5A5-4643-A1F6-08E41D169CEE</gtr:id><gtr:title>The dopamine hypothesis of schizophrenia: version III--the final common pathway.</gtr:title><gtr:parentPublicationTitle>Schizophrenia bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0691a45ce814dfc6ab4c3e6dd94e781"><gtr:id>a0691a45ce814dfc6ab4c3e6dd94e781</gtr:id><gtr:otherNames>Howes OD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0586-7614</gtr:issn><gtr:outcomeId>F1rAxDfhEBx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B428C27F-7AB5-4837-A0EC-49D42FF71B97</gtr:id><gtr:title>Striatal dopamine synthesis capacity in twins discordant for schizophrenia.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e62009071f75acc77285e6fb028d7a8"><gtr:id>6e62009071f75acc77285e6fb028d7a8</gtr:id><gtr:otherNames>Shotbolt P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>KTPWHwz7AK6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF6DA4CE-7AE2-4456-9284-2093BD266501</gtr:id><gtr:title>Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a79e5d2d5d5dfbe5a7d92af4cf5c830a"><gtr:id>a79e5d2d5d5dfbe5a7d92af4cf5c830a</gtr:id><gtr:otherNames>Egerton A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>pm_15289_29_23312565</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4DEEBB7-F8BE-442B-A413-92277D6B8024</gtr:id><gtr:title>A comprehensive review and model of putative prodromal features of bipolar affective disorder.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0691a45ce814dfc6ab4c3e6dd94e781"><gtr:id>a0691a45ce814dfc6ab4c3e6dd94e781</gtr:id><gtr:otherNames>Howes OD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>rjyJuGdN4UR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8689B9E2-A8BC-44B1-82F4-75FCADFC7F51</gtr:id><gtr:title>Acute effect of the anti-addiction drug bupropion on extracellular dopamine concentrations in the human striatum: an [11C]raclopride PET study.</gtr:title><gtr:parentPublicationTitle>NeuroImage</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a79e5d2d5d5dfbe5a7d92af4cf5c830a"><gtr:id>a79e5d2d5d5dfbe5a7d92af4cf5c830a</gtr:id><gtr:otherNames>Egerton A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1053-8119</gtr:issn><gtr:outcomeId>ErMt3iNVGYc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3490324-9D1E-4416-B929-14A6ED754ACC</gtr:id><gtr:title>The role of white matter abnormalities in treatment-resistant depression: a systematic review.</gtr:title><gtr:parentPublicationTitle>Current pharmaceutical design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c681dad2e3b63a4c27bfe632996f708"><gtr:id>2c681dad2e3b63a4c27bfe632996f708</gtr:id><gtr:otherNames>Serafini G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1381-6128</gtr:issn><gtr:outcomeId>545cde89ad0bf8.13768038</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D85112CE-852B-42DF-BF05-CB6CE780AF71</gtr:id><gtr:title>Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0691a45ce814dfc6ab4c3e6dd94e781"><gtr:id>a0691a45ce814dfc6ab4c3e6dd94e781</gtr:id><gtr:otherNames>Howes OD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>5a781fbadfc494.24487571</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3FB4B432-5626-4C00-8310-9DF8812C3AAF</gtr:id><gtr:title>Treatment-Resistant Schizophrenia in a Patient With 17q12 Duplication.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ff54666f6b405661ef7cb8350c72f93"><gtr:id>6ff54666f6b405661ef7cb8350c72f93</gtr:id><gtr:otherNames>Rogdaki M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>5899cdaedd7219.42433095</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F1F59B1-A8EC-44BD-AA7C-BEFCFB5B0037</gtr:id><gtr:title>Misattributing speech and jumping to conclusions: a longitudinal study in people at high risk of psychosis.</gtr:title><gtr:parentPublicationTitle>European psychiatry : the journal of the Association of European Psychiatrists</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d36183be0cf83546985fd8debdab660"><gtr:id>9d36183be0cf83546985fd8debdab660</gtr:id><gtr:otherNames>Winton-Brown TT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0924-9338</gtr:issn><gtr:outcomeId>5899cffbedb3b2.54141088</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2E4EB0E-0BA3-4911-8084-72A60C8E8414</gtr:id><gtr:title>Altered activation and connectivity in a hippocampal-basal ganglia-midbrain circuit during salience processing in subjects at ultra high risk for psychosis.</gtr:title><gtr:parentPublicationTitle>Translational psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f6cef822f5d20e0ff787c52c312664d"><gtr:id>7f6cef822f5d20e0ff787c52c312664d</gtr:id><gtr:otherNames>Winton-Brown T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2158-3188</gtr:issn><gtr:outcomeId>5a7823a84dd505.11129386</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32B58991-744D-4D68-8F7F-A87BC0266372</gtr:id><gtr:title>Cognitive therapy: at last an alternative to antipsychotics?</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b3dfa96a9ff12ea5516b963792374da2"><gtr:id>b3dfa96a9ff12ea5516b963792374da2</gtr:id><gtr:otherNames>Howes O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>545ce212265fe2.91994155</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>409DB27B-9FC4-4E54-931B-3AB5E3CC2A53</gtr:id><gtr:title>Authors' reply.</gtr:title><gtr:parentPublicationTitle>The British journal of psychiatry : the journal of mental science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0691a45ce814dfc6ab4c3e6dd94e781"><gtr:id>a0691a45ce814dfc6ab4c3e6dd94e781</gtr:id><gtr:otherNames>Howes OD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-1250</gtr:issn><gtr:outcomeId>pm_15289_29_23495385</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CAFEBC1E-74E4-4C2F-88FB-6ABD6529066C</gtr:id><gtr:title>Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies.</gtr:title><gtr:parentPublicationTitle>The British journal of psychiatry : the journal of mental science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4b41334629001f83efe0d0b2f5c2da2d"><gtr:id>4b41334629001f83efe0d0b2f5c2da2d</gtr:id><gtr:otherNames>Kambeitz J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-1250</gtr:issn><gtr:outcomeId>545cdfa3877454.57490176</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8FAD7A06-EFB1-4481-98B7-B54E0FDD6940</gtr:id><gtr:title>Practitioner attitudes to clozapine initiation.</gtr:title><gtr:parentPublicationTitle>Acta psychiatrica Scandinavica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/675454352742e6721fdabb543a6b856e"><gtr:id>675454352742e6721fdabb543a6b856e</gtr:id><gtr:otherNames>Gee S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0001-690X</gtr:issn><gtr:outcomeId>pm_15289_29_24004162</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C7908C36-283B-4143-8717-32892FD62009</gtr:id><gtr:title>The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ee90c9d6c29655677832a3f96518646"><gtr:id>1ee90c9d6c29655677832a3f96518646</gtr:id><gtr:otherNames>Ashok AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn><gtr:outcomeId>5a31df785c97c5.53710266</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7AFBC41-2845-4456-B010-D020F89E9C10</gtr:id><gtr:title>Quantification of ligand PET studies using a reference region with a displaceable fraction: application to occupancy studies with [(11)C]-DASB as an example.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6388bd935e8af8c0bb4d3186f2a3278a"><gtr:id>6388bd935e8af8c0bb4d3186f2a3278a</gtr:id><gtr:otherNames>Turkheimer FE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn><gtr:outcomeId>d8K9UEUJmfo</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9FEBA2F3-1382-4FE0-A509-50564BD47AD6</gtr:id><gtr:title>Mapping vulnerability to bipolar disorder: a systematic review and meta-analysis of neuroimaging studies.</gtr:title><gtr:parentPublicationTitle>Journal of psychiatry &amp; neuroscience : JPN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d291d20ff6b7d57155002e6583fb3ce2"><gtr:id>d291d20ff6b7d57155002e6583fb3ce2</gtr:id><gtr:otherNames>Fusar-Poli P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1180-4882</gtr:issn><gtr:outcomeId>pm_15289_29_22297067</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C32402B-ED3A-473E-A03E-ABE4730162C4</gtr:id><gtr:title>Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93ea0bb91d90325b6e0539f945e0a739"><gtr:id>93ea0bb91d90325b6e0539f945e0a739</gtr:id><gtr:otherNames>Lally J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>5899c5e2b40c90.77599422</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2323D4E-CD1C-4E37-8ABC-20EC4497D57A</gtr:id><gtr:title>Schizophrenia: inorganic no more.</gtr:title><gtr:parentPublicationTitle>The lancet. Psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/413ae84d0e24f0badbf8a45ff98faf7f"><gtr:id>413ae84d0e24f0badbf8a45ff98faf7f</gtr:id><gtr:otherNames>Bloomfield MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2215-0366</gtr:issn><gtr:outcomeId>5899c80034b210.07184380</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D290EFAC-B8F8-43A9-9C2C-147907781900</gtr:id><gtr:title>From the prodrome to chronic schizophrenia: the neurobiology underlying psychotic symptoms and cognitive impairments.</gtr:title><gtr:parentPublicationTitle>Current pharmaceutical design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0691a45ce814dfc6ab4c3e6dd94e781"><gtr:id>a0691a45ce814dfc6ab4c3e6dd94e781</gtr:id><gtr:otherNames>Howes OD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1381-6128</gtr:issn><gtr:outcomeId>pm_15289_29_22239576</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>52796296-9FBA-44F7-AA2C-2F6DA71E3AC9</gtr:id><gtr:title>Duration of untreated psychosis and need for admission in patients who engage with mental health services in the prodromal phase.</gtr:title><gtr:parentPublicationTitle>The British journal of psychiatry : the journal of mental science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e1fc6c7dc741f17d75379b1a09057d24"><gtr:id>e1fc6c7dc741f17d75379b1a09057d24</gtr:id><gtr:otherNames>Valmaggia LR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-1250</gtr:issn><gtr:outcomeId>568fcf023fb7b7.85331171</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9953277-F7CA-4C8F-8A5E-CC1A2C92A19A</gtr:id><gtr:title>Altered serotonin transporter binding potential in patients with obsessive-compulsive disorder under escitalopram treatment: [11C]DASB PET study.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30b0216384060a4ecdaf9e25a17b961c"><gtr:id>30b0216384060a4ecdaf9e25a17b961c</gtr:id><gtr:otherNames>Kim E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>568fceff52d628.59069263</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7BA8859E-E3D6-4680-8E3B-E568083167AA</gtr:id><gtr:title>Limbic striatal dopamine D2/3 receptor availability is associated with non-planning impulsivity in healthy adults after exclusion of potential dissimulators.</gtr:title><gtr:parentPublicationTitle>Psychiatry research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e1be79356aa69041dc6a27623523c4d"><gtr:id>3e1be79356aa69041dc6a27623523c4d</gtr:id><gtr:otherNames>Reeves SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0165-1781</gtr:issn><gtr:outcomeId>pm_15289_29_22595510</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1331968-6227-4153-9046-D7CDD3867DE1</gtr:id><gtr:title>Association of Stimulant Use With Dopaminergic Alterations in Users of Cocaine, Amphetamine, or Methamphetamine: A Systematic Review and Meta-analysis.</gtr:title><gtr:parentPublicationTitle>JAMA psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ee90c9d6c29655677832a3f96518646"><gtr:id>1ee90c9d6c29655677832a3f96518646</gtr:id><gtr:otherNames>Ashok AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2168-622X</gtr:issn><gtr:outcomeId>5a31d7786ca3e3.09952562</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>33783CBA-5996-4F24-ABD6-FEAEA8858AD1</gtr:id><gtr:title>Optimising treatment of schizophrenia: the role of adjunctive fluvoxamine.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/675454352742e6721fdabb543a6b856e"><gtr:id>675454352742e6721fdabb543a6b856e</gtr:id><gtr:otherNames>Gee S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>5899bd72b57071.01915731</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7FC7FD9F-F88A-41E0-BBF9-2020231123CB</gtr:id><gtr:title>Effect of Citalopram on Emotion Processing in Humans: A Combined 5-HT[C]CUMI-101 PET and Functional MRI Study.</gtr:title><gtr:parentPublicationTitle>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f36a0b46d325daf7d58d5c21cdcf6fda"><gtr:id>f36a0b46d325daf7d58d5c21cdcf6fda</gtr:id><gtr:otherNames>Selvaraj S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0893-133X</gtr:issn><gtr:outcomeId>5a782955e91299.87830764</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB9E00DB-DCA6-408D-B8A4-35EE8066F23B</gtr:id><gtr:title>The serotonin transporter in depression: Meta-analysis of in vivo and post mortem findings and implications for understanding and treating depression.</gtr:title><gtr:parentPublicationTitle>Journal of affective disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2cdfcb9f0434c41fccd9cd7cf822342e"><gtr:id>2cdfcb9f0434c41fccd9cd7cf822342e</gtr:id><gtr:otherNames>Kambeitz JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0165-0327</gtr:issn><gtr:outcomeId>568fceff7bdcd7.91272896</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0BB725F-CC2F-46A2-A7CE-20FE3CF8A501</gtr:id><gtr:title>Facial and prosodic emotion recognition deficits associate with specific clusters of psychotic symptoms in schizophrenia.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c28ac2f49f2c86660608003e1a06887"><gtr:id>0c28ac2f49f2c86660608003e1a06887</gtr:id><gtr:otherNames>Tseng HH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_15289_29_23818944</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CE14031-5797-47CC-B9FF-8420F7639B1F</gtr:id><gtr:title>Fronto-limbic engagement during moral processing in stimulant users.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/271b8b56c4f70b5ce75faffa5357711a"><gtr:id>271b8b56c4f70b5ce75faffa5357711a</gtr:id><gtr:otherNames>Blackwood NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>5a782b279ad8b2.79254156</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>04E9C107-F760-4D68-B01A-25DE9FC193E0</gtr:id><gtr:title>Adversity in childhood linked to elevated striatal dopamine function in adulthood.</gtr:title><gtr:parentPublicationTitle>Schizophrenia research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a79e5d2d5d5dfbe5a7d92af4cf5c830a"><gtr:id>a79e5d2d5d5dfbe5a7d92af4cf5c830a</gtr:id><gtr:otherNames>Egerton A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0920-9964</gtr:issn><gtr:outcomeId>5899c95ee93a46.17012861</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>214C0AF3-D0DC-43C7-B0FB-B6DEBB236A99</gtr:id><gtr:title>The enduring centrality of dopamine in the pathophysiology of schizophrenia: in vivo evidence from the prodrome to the first psychotic episode.</gtr:title><gtr:parentPublicationTitle>Advances in pharmacology (San Diego, Calif.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6911faec62e64b2ccd758408d951cad1"><gtr:id>6911faec62e64b2ccd758408d951cad1</gtr:id><gtr:otherNames>Bonoldi I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1054-3589</gtr:issn><gtr:outcomeId>pm_15289_29_24054146</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D7D1765-383D-4998-973D-43D495392D4B</gtr:id><gtr:title>Julius Wagner-Jauregg, 1857-1940.</gtr:title><gtr:parentPublicationTitle>The American journal of psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0691a45ce814dfc6ab4c3e6dd94e781"><gtr:id>a0691a45ce814dfc6ab4c3e6dd94e781</gtr:id><gtr:otherNames>Howes OD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0002-953X</gtr:issn><gtr:outcomeId>ad7W2PHqSxm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3DB1ECFB-2427-42EF-818F-4F16D5843C48</gtr:id><gtr:title>Does environmental confounding mask pleiotropic effects of a multiple sclerosis susceptibility variant on vitamin D in psychosis?</gtr:title><gtr:parentPublicationTitle>NPJ schizophrenia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a4628cec98cde5dd165a24a8e27e3c8"><gtr:id>2a4628cec98cde5dd165a24a8e27e3c8</gtr:id><gtr:otherNames>Iyegbe CO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2334-265X</gtr:issn><gtr:outcomeId>5899cf3c08f5a5.68038967</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB038FBF-C2EC-4E95-ACE5-A7F07333181B</gtr:id><gtr:title>Inflammation and the neural diathesis-stress hypothesis of schizophrenia: a reconceptualization.</gtr:title><gtr:parentPublicationTitle>Translational psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0691a45ce814dfc6ab4c3e6dd94e781"><gtr:id>a0691a45ce814dfc6ab4c3e6dd94e781</gtr:id><gtr:otherNames>Howes OD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2158-3188</gtr:issn><gtr:outcomeId>5a782a852bae86.09063352</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC50D8A6-3A25-478E-AB93-4240FBF0EF86</gtr:id><gtr:title>The relationship between reward and punishment processing and the 5-HT1A receptor as shown by PET.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/763f1412d2c3e5d95ae6bb5de85ecb58"><gtr:id>763f1412d2c3e5d95ae6bb5de85ecb58</gtr:id><gtr:otherNames>Faulkner P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>545ce38058f4a8.89994436</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B0F8F1C-5867-45DB-9486-B5E3F153FB0F</gtr:id><gtr:title>Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49b1a2224b337a1dda5d402fdfa5fb51"><gtr:id>49b1a2224b337a1dda5d402fdfa5fb51</gtr:id><gtr:otherNames>Stone JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>AdVPTxyQoVh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC85BA2E-26A0-43C4-AC1E-8DD973DCA19A</gtr:id><gtr:title>The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc968016bd4e9ed2429481e2b3cf7b5f"><gtr:id>fc968016bd4e9ed2429481e2b3cf7b5f</gtr:id><gtr:otherNames>Kokkinou M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn><gtr:outcomeId>5a7824227d6270.39978412</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>778B41A3-C30A-4F8D-9640-056B4E35FCEE</gtr:id><gtr:title>Dopamine and the aberrant salience hypothesis of schizophrenia.</gtr:title><gtr:parentPublicationTitle>World psychiatry : official journal of the World Psychiatric Association (WPA)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0691a45ce814dfc6ab4c3e6dd94e781"><gtr:id>a0691a45ce814dfc6ab4c3e6dd94e781</gtr:id><gtr:otherNames>Howes OD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1723-8617</gtr:issn><gtr:outcomeId>5899cc2707bd03.01427973</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>612CA4F4-4C1C-476E-8857-9A50DE2C3CC2</gtr:id><gtr:title>Elevated striatal dopamine function linked to prodromal signs of schizophrenia.</gtr:title><gtr:parentPublicationTitle>Archives of general psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0691a45ce814dfc6ab4c3e6dd94e781"><gtr:id>a0691a45ce814dfc6ab4c3e6dd94e781</gtr:id><gtr:otherNames>Howes OD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0003-990X</gtr:issn><gtr:outcomeId>nvUh8TkP3Nz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>21D3A6B5-AB27-4949-A538-3BFFD76197F7</gtr:id><gtr:title>Heterogeneity and Homogeneity of Regional Brain Structure in Schizophrenia: A Meta-analysis.</gtr:title><gtr:parentPublicationTitle>JAMA psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/633082159814b03e4c41b7972cf83195"><gtr:id>633082159814b03e4c41b7972cf83195</gtr:id><gtr:otherNames>Brugger SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2168-622X</gtr:issn><gtr:outcomeId>5a782361d6ddd7.21459946</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34203610-CAC5-4D5C-A653-FB779FDB5C8B</gtr:id><gtr:title>Is antipsychotic treatment linked to low bone mineral density and osteoporosis? A review of the evidence and the clinical implications.</gtr:title><gtr:parentPublicationTitle>Human psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d5ede7c13d1b7063f50c98a4f79b69e"><gtr:id>7d5ede7c13d1b7063f50c98a4f79b69e</gtr:id><gtr:otherNames>Crews MP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0885-6222</gtr:issn><gtr:outcomeId>pm_15289_29_22228316</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68CB8445-E89C-4E36-BEA0-485200EB449A</gtr:id><gtr:title>Multimodal functional imaging investigation before and after the onset of psychosis.</gtr:title><gtr:parentPublicationTitle>The international journal of neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d291d20ff6b7d57155002e6583fb3ce2"><gtr:id>d291d20ff6b7d57155002e6583fb3ce2</gtr:id><gtr:otherNames>Fusar-Poli P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1461-1457</gtr:issn><gtr:outcomeId>mQbTudDxZfu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11FA0587-81A3-4BDD-B108-1BED173E0751</gtr:id><gtr:title>Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c15e111b142ba9fa72a41273b026519d"><gtr:id>c15e111b142ba9fa72a41273b026519d</gtr:id><gtr:otherNames>Goodwin GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>5899cad857d1b8.61619880</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF710FC8-CBDC-40F1-9043-4CA83D5DF8C2</gtr:id><gtr:title>Pseudohallucinations versus true hallucinations in prodromal psychosis: does it really matter?</gtr:title><gtr:parentPublicationTitle>The Journal of clinical psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d291d20ff6b7d57155002e6583fb3ce2"><gtr:id>d291d20ff6b7d57155002e6583fb3ce2</gtr:id><gtr:otherNames>Fusar-Poli P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0160-6689</gtr:issn><gtr:outcomeId>mDKKGniqtkS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2716DB5B-E0FC-4889-9EAD-C53F88C0264F</gtr:id><gtr:title>Commentary on a study of the prevalence of mental disorders by Breslau et al.</gtr:title><gtr:parentPublicationTitle>Journal of psychiatric research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/413ae84d0e24f0badbf8a45ff98faf7f"><gtr:id>413ae84d0e24f0badbf8a45ff98faf7f</gtr:id><gtr:otherNames>Bloomfield MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-3956</gtr:issn><gtr:outcomeId>568fda562f3361.37480870</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1CB2D8B2-BA0E-4B43-BEEC-205CC0D641CC</gtr:id><gtr:title>Impaired verbal self-monitoring in individuals at high risk of psychosis.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/73f23282d4aafb49f167236653b6d815"><gtr:id>73f23282d4aafb49f167236653b6d815</gtr:id><gtr:otherNames>Johns LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>kwPVGnkEpU2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4B48CF5-20A5-4987-AAF9-75EACBBB9D4E</gtr:id><gtr:title>Sex hormone augmentation as an adjunctive treatment in schizophrenia.</gtr:title><gtr:parentPublicationTitle>Journal of clinical psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0691a45ce814dfc6ab4c3e6dd94e781"><gtr:id>a0691a45ce814dfc6ab4c3e6dd94e781</gtr:id><gtr:otherNames>Howes OD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0271-0749</gtr:issn><gtr:outcomeId>VXuLkKN173y</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6CFEBDFB-5399-412F-9EBB-6D3C8CCC79B5</gtr:id><gtr:title>Cortical GABA in Subjects at Ultra-High Risk of Psychosis: Relationship to Negative Prodromal Symptoms.</gtr:title><gtr:parentPublicationTitle>The international journal of neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14b4c0a6b15f22e1b9e8682528fa2337"><gtr:id>14b4c0a6b15f22e1b9e8682528fa2337</gtr:id><gtr:otherNames>Modinos G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1461-1457</gtr:issn><gtr:outcomeId>5a7821643c06a6.65154426</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>09480551-CAC0-4D54-8F62-B5B82A35375D</gtr:id><gtr:title>Minocycline reduces chronic microglial activation after brain trauma but increases neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/071e882d6d5617fac73b55ac1d8145b1"><gtr:id>071e882d6d5617fac73b55ac1d8145b1</gtr:id><gtr:otherNames>Scott G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5a781f7d3feb53.33072342</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>259B197D-285D-40A8-A011-CC9F124122CD</gtr:id><gtr:title>A Test of the Transdiagnostic Dopamine Hypothesis of Psychosis Using Positron Emission Tomographic Imaging in Bipolar Affective Disorder and Schizophrenia.</gtr:title><gtr:parentPublicationTitle>JAMA psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a84d5164320bf6da1e277517de582069"><gtr:id>a84d5164320bf6da1e277517de582069</gtr:id><gtr:otherNames>Jauhar S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2168-622X</gtr:issn><gtr:outcomeId>5a7821043466e5.89473051</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A7A8913-1919-470E-86DE-0D0A47A03CDF</gtr:id><gtr:title>Dopaminergic basis of salience dysregulation in psychosis.</gtr:title><gtr:parentPublicationTitle>Trends in neurosciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d36183be0cf83546985fd8debdab660"><gtr:id>9d36183be0cf83546985fd8debdab660</gtr:id><gtr:otherNames>Winton-Brown TT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0166-2236</gtr:issn><gtr:outcomeId>545ce3807d84c0.30916687</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>042F46E2-42C0-4C38-9FB3-BBA2EA350B9C</gtr:id><gtr:title>Sexual dysfunction in people with prodromal or first-episode psychosis.</gtr:title><gtr:parentPublicationTitle>The British journal of psychiatry : the journal of mental science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1f97baa8e5ebb1e342f4eaf589b393a"><gtr:id>b1f97baa8e5ebb1e342f4eaf589b393a</gtr:id><gtr:otherNames>Marques TR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-1250</gtr:issn><gtr:outcomeId>pm_15289_29_22700081</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28F6BE39-2042-4331-BE8B-6B3FB94FC4F4</gtr:id><gtr:title>First-Episode Schizophrenia and Diabetes Risk-Reply.</gtr:title><gtr:parentPublicationTitle>JAMA psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a65bfc1b8abd7d7955764a76ed2fb2a7"><gtr:id>a65bfc1b8abd7d7955764a76ed2fb2a7</gtr:id><gtr:otherNames>Pillinger T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2168-622X</gtr:issn><gtr:outcomeId>5a7829fdc5e682.02390614</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7C10ACD9-6C26-4E5C-970B-F25FB65FF873</gtr:id><gtr:title>The development, past achievements, and future directions of brain PET.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9807848e309ce5cd2a8c11807b9fab1d"><gtr:id>9807848e309ce5cd2a8c11807b9fab1d</gtr:id><gtr:otherNames>Jones T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn><gtr:outcomeId>pm_15289_29_22434067</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0B31F70-5B8E-483A-8CA5-762771D7581E</gtr:id><gtr:title>Biallelic Mutations in PDE10A Lead to Loss of Striatal PDE10A and a Hyperkinetic Movement Disorder with Onset in Infancy.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c2b657386a4a4105e8345c404cba4b3"><gtr:id>2c2b657386a4a4105e8345c404cba4b3</gtr:id><gtr:otherNames>Diggle CP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>5899ca2b785327.52173905</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4FDDAA3-82C1-4A7C-A6AC-9AD4A56C4528</gtr:id><gtr:title>Presynaptic dopaminergic function: implications for understanding treatment response in psychosis.</gtr:title><gtr:parentPublicationTitle>CNS drugs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6911faec62e64b2ccd758408d951cad1"><gtr:id>6911faec62e64b2ccd758408d951cad1</gtr:id><gtr:otherNames>Bonoldi I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1172-7047</gtr:issn><gtr:outcomeId>545ce21298eee9.47761454</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>02AF2CB9-8A22-4E32-9C8B-1BE82855DBC7</gtr:id><gtr:title>Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8351ab06ac06ebf444f6bf4346a232c"><gtr:id>b8351ab06ac06ebf444f6bf4346a232c</gtr:id><gtr:otherNames>Demjaha A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>5a7829fe5984e0.09127079</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EEBF2AF6-D3D5-4245-A81F-26790AF813C6</gtr:id><gtr:title>History of cannabis use is not associated with alterations in striatal dopamine D2/D3 receptor availability.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ef610bf70a2414f028fadc10f8091b2"><gtr:id>9ef610bf70a2414f028fadc10f8091b2</gtr:id><gtr:otherNames>Stokes PR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>JWRMN9MpmEk</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F3F5AFF6-366E-44EA-9101-D4E36BA69AAC</gtr:id><gtr:title>A neurobiological hypothesis for the classification of schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic).</gtr:title><gtr:parentPublicationTitle>The British journal of psychiatry : the journal of mental science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0691a45ce814dfc6ab4c3e6dd94e781"><gtr:id>a0691a45ce814dfc6ab4c3e6dd94e781</gtr:id><gtr:otherNames>Howes OD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-1250</gtr:issn><gtr:outcomeId>545cdfa3adc4e6.02338052</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE49A539-A49B-4365-AF95-7CE51FF5D8D5</gtr:id><gtr:title>Regional Differences in Serotonin Transporter Occupancy by Escitalopram: An [C]DASB PK-PD Study.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacokinetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30b0216384060a4ecdaf9e25a17b961c"><gtr:id>30b0216384060a4ecdaf9e25a17b961c</gtr:id><gtr:otherNames>Kim E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0312-5963</gtr:issn><gtr:outcomeId>5899c800089fc3.14168746</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10E3D2C3-6437-49A6-99CB-5EA197CDE687</gtr:id><gtr:title>Optimising treatment of refractory schizophrenia.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c975fa03eb54774fe421ed0b63329471"><gtr:id>c975fa03eb54774fe421ed0b63329471</gtr:id><gtr:otherNames>Beck K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>pm_15289_29_23568576</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>31F1CC62-6A9B-4EB3-AD26-13755017C414</gtr:id><gtr:title>Reduced mismatch negativity predates the onset of psychosis.</gtr:title><gtr:parentPublicationTitle>Schizophrenia research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af50a386b662467f252f056120383a71"><gtr:id>af50a386b662467f252f056120383a71</gtr:id><gtr:otherNames>Shaikh M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0920-9964</gtr:issn><gtr:outcomeId>tQ3pdtFd8j9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FCC576DC-75FD-419D-A8CD-0379737C5B52</gtr:id><gtr:title>Auditory verbal hallucinations and continuum models of psychosis: A systematic review of the healthy voice-hearer literature.</gtr:title><gtr:parentPublicationTitle>Clinical psychology review</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c446fa0bff6f451bac1159a6d51f70cc"><gtr:id>c446fa0bff6f451bac1159a6d51f70cc</gtr:id><gtr:otherNames>Baumeister D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0272-7358</gtr:issn><gtr:outcomeId>5899c5067d14e9.84529299</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U120097115</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>3C193D18-12BD-4B15-8347-037BA623E0FF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Mental Health</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>